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[57] ABSTRACT 
Quaternary pyridinium compounds, their use in inhibit-
ing acetylcholinesterase, their roles in the prophylaxis 
and treatment of organophosphate poisoning, their roles 
in anticholinesterase therapy and their roles as agents 
mimicking or opposing the actions of the natural neuro-
transmitter acetylcholine. 
3 Claims, No Drawings 
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1 2 
esterase (Bedford, C. D., Harris, R. N., III, Howd, R. 
A., Goff, D. A., Koolpe, G. A., Petesch, M., Koplovitz, 
I., Sultan, W. E., and Musallam, H. A., J. Med. Chem. 
1989, 32, 504; Bedford, C. D., Harris, R. N., Howd, R. 
QUATERNARY PYRIDINIUM COMPOUNDS 
ST A TEMENT OF GOVERNMENT INTEREST 
This invention was made with Government support 
under Contract No. DAMD17-85-C-5143 awarded by 
the U.S. Army Medical Research and Development 
Command. The Government has certain rights in the 
invention. 
5 A., Goff, D. A., Koolpe, G. A., Petesch, M., Miller, A., 
Nolen, H. W., III, Musallam, H. A., Pick, R. 0., Jones, 
D. E., Koplovitz, I., and Sultan, W. E., J. Med. Chem. 
1989, 32, 493; Benschop, H. P., Van der Berg, G. R., 
Van der Hooidonk, C., DeJong, L. P.A., Kientz, C. E., 
BACKGROUND OF THE INVENTION 
10 Berends, F., Kepner, L. A., Meeter, E., and Visser, R. 
1. Field of the Invention 
This invention relates to a novel class of quaternary 
pyridinium compounds useful for selectively inhibiting 
acetylcholinesterase (AChE) and to their use as nerve 15 
agent antidotes and prophylactics. We have found that 
certain quaternary pyridinium derivatives can offer in 
vivo protection against the nerve agents Soman (GD) 
and Tabun (GA) and therefore they can also offer pro-
tection against other organophophate poisons. We have 20 
also found that certain quaternary pyridinium deriva-
tives can effectively increase the rate of survival of 
experimental animals exposed to the nerve agents GD 
and GA and therefore they can also serve as antidotes 
against other organophosphate poisons. All of the ac- 25 
tive pyridinium compounds are good AChE inhibitors 
in vitro and therefore they can also be used to treat 
conditions where a cholinergic deficit leading to pathol-
ogy can be ameliorated by administration of an anticho-
linesterase agent. All of the pyridinium compounds 30 
P. L. S., J. Med. Chem. 1979, 22, 1306; Grifantini, M., 
Martelli, S., and Stein, M. L., J. Med. Chem. 1973, 16, 
937, incorporated herein by reference). 
c1-0 
+N CH= NOH 
I 
CH3 
2-PAM Chloride 
HI-6 
described herein can have additional beneficial effects s1· ce ·1 ·s d"ffi It t t" t d h h J t d n 1 1 1 1cu o reac 1va e age p osp ony a e 
in living organisms by virtue of their resemblance to the AChE, prophylactic treatment with AChE inhibitors 
natural neurotransmitter acetylcholine and their ability may be the pre,.erred alternati· AChE · t t d 1, ve. 1s pro ec e 
to act on cholinergic receptors. 
3
-
, from nerve agents by preadministration of an AChE 2. Description of the Related Art ' 
Development of an effective antidote to organophos- carbamylating agent such as pyridostigmine or physo-
phorus (OP) nerve agents has been a goal of medicinal stigmine. These carbamates react covalently with 
chemists since the development of Tabun in Germany AChE at the active site serine, but the carbamylated 
in 1937. OP agents react covalently with the active site enzyme is hydrolyzed quickly to active enzyme (30 
serine hydroxyl group of acetylcholinesterase (AChE) 40 min.) while phosphonylated AChE requires several 
to form a stable phosphonyl ester which requires up to hours or days for regeneration of active AChE (Main, 
30 days for hydrolysis (Main, A. R. In Biology of Cho- A. R., vide supra). Blocking AChE for a short period of 
1. · F t. G Jdb A M H · I Ed time allows destruction of the OP agent by uncatalyzed merg1c unc 10n; o erg, . ., anm, ., s.; 
Raven Press: New York, 1976; pp. 269-353, incorpo- hydrolysis or reaction with enzymes such as carboxyles-
rated herein by reference). Excess acetylcholine accu- 45 terase or pseudocholinesterase (Harris, L. W., Stitcher, 
mulates and causes severe neurological imbalance, res- D. L., and Heyl, W. C., Life Sci. 1980, 26, 1885, incorpo-
piratory paralysis, and death (Koelle, G. B. In The Phar- rated herein by reference). Unfortunately, physostig-
macological Basis of Therapeutics; Goodman, L., and mine is very toxic and small doses can be lethal. Fur-
Gilman, A., Eds.; MacMillan: New York, 1975; p. 404, thermore, physostigmine is unstable and would rapidly 
incorporated herein by reference). Pyridinium aldox- 50 decompose in the battlefield. Both carbamates are effec-
imes (2-PAM and HI-6, see structures below) are cur- tive only when combined with several other drugs 
rently used in conjunction with an acetylcholine antag- (Heyl, W. C., Harris, L. W., and Stitcher, D. L., Drug 
onist (atropine) to reactivate the phosphonylated serine Chem. Toxicol. 1980, 3, 319, incorporated herein by 
hydroxyl group of AChE after poisoning occurs (Lead- reference). 
beater, L., Inns, R. H., and Rylands, J. M. Fund. App. 55 Other approaches to prophylaxis against OP poison-
Toxicol. 1985, 5, S225, incorporated herein by refer- ing have involved the use of cyclic organophosphates to 
ence). This treatment is ineffective against GD and GA temporarily block AChE (Ashani, Y., Leader, H., 
because the initially formed enzyme bound alkyl phos- Raveh, L., Bruckstein, R. and Spiegelstein, M., J. Med. 
phonate esters undergo rapid aging with loss of the Chem. 1983, 26, 145, incorporated herein by reference), 
alkoxy side chain to form a negatively charged phos- 60 reduction of AChE levels by inhibition of choline ace-
phonyl mono ester (Wolthuis, 0. L., Berends, F., and tyl transferase (Gray, A. P., Platz, R. D., Henderson, T. 
Meeter, E., Fund. Appl. Toxicol. 1981, l, 183, incorpo- R., Chang, T. C. P., Takahashi, K. and Dretchen, K. L.,' 
rated herein by reference). The negative charge on this J. Med. Chem. 1988, 31, 807, incorporated herein by 
mono ester repels nucleophiles which are required to reference), and the µse of antimuscarinic a-adrenergic 
dephosphonylate the enzyme. 65 agonists (e.g., clonidine) to block the release of acetyl-
Other approaches to OP antidotes have dealt with choline from presynaptic nerve terminals (Buccafusco, 
changes in the heteroaromatic ring system in order to J. J. and Aronstam, R. S., J. Pharmacol. Exp. Ther. 1986, 
improve the reactivation of OP-inhibited acetylcholin- 239, 43, incorporated herein by reference). 
3 
5,180,831 
Many oxime, semicarbazone, hydrazone and acyl 
hydrazone derivatives of 2-formyl-3-hydroxy-l-methyl-
pyridinium chloride described herein incorporate both, 
a nucleophile to displace the phosphonate from the 
serine hydroxyl group of AChE and an additional hy- 5 
drogen bonding group (hydroxyl) to neutralize the neg-
ative charge on the aged phosphonate mono ester. In 
addition, the parent 3-hydroxypyridinium derivatives 
were converted into various carbamates since these are 
pyridostigmine analogs and can react covalently with 10 
AChE and thus provide protection from OP agents. 
DETAILED DESCRIPTION OF THE 
INVENTION .. 
Aldoxime, hydrazone, semicarbazone and acyl hy- 15 
drazone derivatives of 2-formyl-1-substituted pyridin-
ium compounds are good inhibitors of acetylcholines-
terase (AChE) and can displace a nerve agent from the 
enzyme active site or protect the latter from attack by a 
nerve agent. Therefore these structures can be used as 20 
antidotes and prophylactics against nerve agents or 
other organophosphate poisons. Furthermore, it is pos-
sible that the carbamates act first as prophylactics 
against OP poisoning and that the reaction products 
d . . ) . f h 25 (3-hydroxy envat1ves act as reacuvators o p os-
phonylated AChE (see below). Herein we describe one 
instance of this prophylactic/prodrug concept. 
01 OCONR. "R""_,..,.----'-A.:..:C:..:..:h;;.E--.,...,.,-::,,,.~ l Jl Nu = nucleophile 7 
N CH=Nu 
-·1 
R" 
30 
4 
-continued 
,('Xx 
B N_ CH=NOR1 
I 
z 
with any counterion to make pharmaceutically accept-
able salts, wherein 
Z is selected from the group consisting of C1-6 alkyl, 
C1-6 alkyl with an attached phenyl group, C1-6 alkyl 
with an attached naphtyl group, C1-6 alkyl with two 
attached phenyl groups, C1-6 alkyl with an attached 
phenyl group mono, di, or trisubstituted with J, C1-6 
alkyl with two attached phenyl groups mono, di, or 
trisubstituted with J, C1-6 alkyl with an attached naph-
tyl group mono, di, or trisubstituted with J, 
wherein J is selected from the group consisting of 
halogen, COOH, OH, CN, N02, NH2, C1-6 alkyl, C1-6 
alkoxy, C1-6 alkylamine, C1-6 alkyl-0-CO-, C1-6 
alkyl-0-CO-NH-, C1-6 alkyl-NH-CO-NH-, 
C1-6 alkyl-NH-C0-0-, C1-6 alkyl NH-CO-, 
(C1-6 alkyl)2N-CO-, 
wherein X is selected from the group consisting of 
OH, C1-6 alkyl-NH-C0-0-, (C1-6 alkyl)i-
N-C0-0-, C1-6 fluoroalkyl-NH-C0-0-, (C1-6 
fluoroalkyl)2-NH-CO-O-, 
Prophylactic 
O OH 40 
wherein R1 is selected from the group consisting of 
C1-6 alkyl with an attached phenyl group, C1-6 alkyl 
with two attached phenyl groups, C1-6 alkyl with an 
attached phenyl group mono, di, or trisubstituted with 
K, C1-6 alkyl with two attached phenyl groups mono. 
35 di, or trisubstituted with K, C1-6 alkyl with an attached 
naphtyl group, C1-6 alkyl with an attached naphtyl 
group mono, di, or trisubstituted with K. C1-6 alkyl-T, 
wherein T is selected from the group consisting of 
formula (I) and formula (II), 
" 
_N CH=Nu 
I 
R' 
Reactivator 
45 
In addition to their AChE inhibitory properties, these 
derivatives can act on cholinergic receptors in the ner-
vous system either to mimic or to oppose the effects of 
the natural neurotransmitter acetylcholine. Therefore 
these structures can also be used in the treatment of 50 
conditions such as Myasthenia Gravis, Alzheimer's 
disease and adult Down's syndrome where a choliner-
gic deficit leading to pathology can .be ameliorated by 
administration of a cholinomimetic or an anticholines-
terase agent. These structures can also act on the cardi- 55 
ovascular system to produce an antihypertensive effect; 
they can be useful in the treatment of glaucoma; they 
can enhance bowel tone and motility. 
The novel substituted pyridinium derivatives have 
the following structural formulas: 60 
R' 
I 
-]'.;--R" 
I 
R"' 
Formula I 
Formula II 
wherein R', R", and R'" are selected from the group 
consisting of H, C1-6 alkyl, C1-6 fluoroalkyl, C1-6 alkyl 
with an attached phenyl group, C1-6 alkyl with an at-
tached phenyl group mono, di, or trisubstituted with K. 
C1-6 fluoroalkyl with an attached phenyl group mono, 
di, or trisubstituted with K, 
wherein K is selected from the group consisting of 
halogen, COOH, OH, CN, N02, NH2, C1-6 alkyl, C1-6 
alkoxy, C1-6 alkylamine, C1-6 alkyl-0-CO-, C1-6 
alkyl-0-CO-NH-, C1-6 alkyl-NH-CO-NH-, 
C1-6 alkyl-NH-C0-0-, C1-6 alkyl NH-CO-,. 
(C1-6 alkyl)2N-CO-, x~ l Jl and wherein B is selected from the group consisting of H. 65 C1-6 alkyl. 
N_ CH=NOR1 
I 
z 
Alternatively the novel quaternary pyridinium com-
pounds are represented by the following structural for-
mulas: 
5 
5, 180,831 
6 
-continued 
xll ~ I Y and 
" II N~ CH=NNH-C-NR2R3 5 
Formula II 
I 
z 
LJ:x fi 
B N+ CH=NNH-C-NR2R3 I. 
wherein R', R", and R'" are selected' from the group 
consisting of H, C1-6 alkyl, C1-6 fluoroalkyl, C1-6 alkyl 
with an attached phenyl group, C1-6 alkyl with an at-
10 tached phenyl group mono, di, or trisubstituted with K, 
CJ-6 fluoroalkyl with an attached phenyl group mono, 
di, or trisubstituted with K, 
z 
15 with any counterion to make pharmaceutically accept· 
able salts, wherein 
Y is 0 or S, 
wherein R2 is selected from the group consisting of 
H, C1-6 alkyl, phenyl, C1-6 alkyl with an attached 
20 phenyl group, C1-6alkyl with an attached phenyl group 
mono, di, or trisubstituted with K, C1-6 alkyl with an 
attached naphtyl group, C1-6 alkyl with an attached 
naphtyl group mono, di, or trisubstituted with K, 
wherein R3 is selected from the group consisting of 25 H, C1-6 alkyl, phenyl, C1-6 alkyl with an attached 
phenyl group, C1-6alkyl with an attached phenyl group 
mono, di, or trisubstituted with K. 
Alternatively the novel quaternary pyridinium com-
pounds are represented by the following structural for- 30 
mulas: 
X1ll I Y and 
" II N_ CH=NNH-C-R.i 
35 
I 
z 
wherein K is selected from the group consisting of 
halogen, COOH, OH, CN, N02, NH2, C1-6 alkyl, C1-6 
alkoxy, C1-6 alkylamine, C1-6 alkyl-0-CO-, C1-6 
alkyl-0-CO-NH-, C1-6 alkyl-NH-CO-NH-, 
C1-6 alkyl-NH-C0-0-, C1-6 alkyl NH-CO-, 
(C1-6 alkyl)2N-CO-. 
Alternatively the novel quaternary pyridinium com-
pounds are represented by the following structural for-
mulas: 
x~ l ~ and 
N ~ CH=NNRsR6 I. 
z 
LJ:x 
B N_ CH=NNRsRo I. 
z 
with any counterion to make pharmaceutically accept-
able salts, wherein 
R5 is selected from the group consisting of C1-6 alkyl, X1 
y 
II 
B N_ CH=NNH-C-R4 
I 
40 phenyl, C1-6 alkyl with an attached phenyl group, C1-6 
alkyl with an attached phenyl group mono, di, or trisub-
stituted with K, C1-6 alkyl with an attached naphtyl 
group, C1-6alkyl with an attached naphtyl group mono, 
z 
with any counterion to make pharmaceutically accept-
able salts, wherein 
45 
X1 is selected from the group consisting of H. OH, 
C1-6 alkyl-NH-C0-0-, (C1-6 alkyl)i-N-C0-0-, 
C1-6 fluoroalkyl-NH-C0-0-, (CJ-6 fluoroalkyl)2- 50 
NH-C0-0-, 
wherein ~ is selected from the group consisting of 
C1-6 alkyl with a pyridinium ring attached through 
nitrogen, C1-6 alkyl with a pyridinium ring attached 
through nitrogen and mono, di, or trisubstituted with K, 55 
C1-6 alkyl with a quinolinium ring attached through 
nitrogen and mono, di, or trisubstituted with K, C1-6 
alkyl with an isoquinolinium ring attached through 
nitrogen and mono, di, or trisubstituted with K, C1-6 
alkyl-T, 60 
wherein T is selected from the group consisting of 
formula (I) and formula (II), 
R' 
I 
-N+-R" 
I 
R"' 
Formula I 
65 
di, or trisubstituted with K, 
wherein R6 is selected from the group consisting of 
H, C1-6 alkyl, phenyl, C1-6 alkyl with an attached 
phenyl group, C1-6alkyl with an attached phenyl group 
mono, di, or trisubstituted with K. 
Alternatively the novel quaternary pyridinium com-
pounds are represented by the following structural for-
mulas: 
x~ l ~ and 
N CH=NOH 
I+ 
z 
LJ:x 
B N_ CH=NOH 
I 
z 
with any counterion to make pharmaceutically accept· 
able salts. 
5,180,831 
7 
Alternatively the novel quaternary pyridinium com-
pounds are represented by the following structural for-
mula: 
~ y l Jl II 
N CH=NNH-C-NR7Rg 
, ... 
z 
with any counterion to make pharmaceutically accept-
able salts, wherein 
R1 is selected from the group consisting of Ct-6 alkyl, 
phenyl, Ct-6 alkyl with an attached phenyl group, C1-6 
alkyl with an attached phenyl group mono, di, or trisub-
stituted with K, C1-6 alkyl with an attached naphtyl 
group, C1-6alkyl with an attached naphtyl group mono, 
di, or trisubstituted with K, -CO-C1-6 alkyl, 
-CO-C1-6alkyl with an attached phenyl group mono, 
di, or trisubstituted with K, 
wherein Rs is selected from the group consisting of 
8 
0-( l-Naphtylmethyl)-N-(3-hydroxy- l-me~hyl-2-
pyridinemethylene) hydroxylamine chloride. 
0-(2-Methyl- l-naphtylmethyl)-N-(3-hydroxy- l-meth-
yl-2-pyridinemethylene) hydroxylamine chloride. 
5 0-(2,3,4-Trimethoxybenzyl)-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride. 
0-(3,3-Dipheny I propyl)-N-(3-h ydroxy-1-meth y 1-2-
pyridinemethy lene) hydroxylamine chloride. 
0-( 1-Naphtylmethyl)-N-( 1 ,6-dimethyl-3-hydroxy-2-
10 pyridinemethylene) hydroxylamine chloride. 
0-(2-Methyl- l-naphtylmethyl)-N-( 1, 6-dimethy 1-3-
hydroxy-2-pyridinemethy lene) hydroxylamine chlo-
ride. 
0-Methy 1-N-( 3-hydroxy-1-methy 1-2-pyridinemethy-
15 Jene) hydroxylamine chloride (le). 
O-Methyl-N-(l,6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydroxylamine chloride. 
0-[2-( l-Methyl-1-piperidinium]ethyl)-N-(3-hydroxy- l-
methyl-2-pyridinemethylene) hydroxylamine dichlo-
20 ride. 
0-[2-(Trimethylammonium)ethyl)-N-(3-hydroxy-l- · 
methyl-2-pyridinemethylene) hydroxylamine dichlo-
ride. 
H, C1-6 alkyl, phenyl, C1-6 alkyl with an attached 
phenyl group, C1-6alkyl with an attached phenyl group 25 
mono, di, or trisubstituted with K. 
O-(p-Chlorobenzyl)-N-(3-hydroxy- l-methy 1-2-
pyridinemethy lene) hydroxylamine chloride (ld). 
0-(p-Cyanobenzy l)-N-(3-hydroxy- l-methyl-2-
pyridinemethy lene) hydroxylamine chloride. 
0-(2-H ydroxy-4-nitrobenzyl)-N-( 3-hydrox y-1-meth y 1-
2-pyridinemethylene) hydroxylamine chloride. 
Alternatively the novel quaternary pyridinium com-
pounds are represented by the following structural for-
mula: 
(l 
N CH=NOR9 , ... 
z 
with any counterion to make pharmaceutically accept-
able salts, wherein 
30 O-(p-Carboxybenzyl)-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride. 
O-(p-Chlorobenzyl)-N-(l,6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydroxylamine chloride. 
O-(p-Cyanobenzyl)-N-(l,6-dimethyl-3-hydroxy-2-
35 pyridinemethylene) hydroxylamine chloride. 
0-(2-Hydroxy-4-nitrobenzyl)-N-(l,6-dimethyl-3-
hydroxy-2-pyridinemethylene) hydroxylamine chlo-
ride. 
R9 is selected from the group consisting of Ct-6 alkyl 40 
with an attached phenyl group, C1-6 alkyl with two 
attached phenyl groups, C1-6 alkyl with an attached 
phenyl group mono, di, or trisubstituted with K, Ct-6 
alkyl with two attached phenyl groups mono, di, or 
trisubstituted with K, C1-6 alkyl with an attached naph- 45 
tyl group, C1-6 alkyl with an attached naphtyl group 
mono, di, or trisubstituted with K. 
O-(p-Methoxybenzyl)-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride (le). 
0-(p-Dimethy laminocarbony loxy benzy I)-N-( 3-
hydroxy- l -methy 1-2-pyridinemethylene) hydroxy-
lamine chloride. 
0-(p-Propylaminocarbonyl benzyl)-N-(3-hydroxy-l-
methyl-2-pyridinemethylene) hydroxylamine chlo-
ride. 
0-(p-Ethoxycarbonyl benzyl)-N-(3-hydroxy-1-methyl-
2-pyridinemethylene) hydroxylamine chloride. The following compounds are representative of the 
invention: 
O-Benzyl-N-(l-methyl-2-pyridinemethylene) hydroxy-
lamine chloride (la). 
0-(Diphen y lmethy 1)-N-( 1-methy 1-2-pyridinemethy-
lene) hydroxylamine chloride. 
0-(p-Chlorobenzy 1)-N-(1-methy 1-2-pyridinemethylene) 
hydroxylamine chloride. 
0-(p-Methoxybenzyl )-N-( l -methyl-2-pyridinemeth y-
lene) hydroxylamine chloride. 
0-( 1-Naphtylmethyl)-N-( 1-meth y 1-2-pyridinemethy-
lene) hydroxylamine chloride. 
0-(2-Methyl- l-naphtylmethyl)-N-(l-methyl-2-
pyridinemethylene) hydroxylamine chloride. 
0-(2,3,4-Trimethoxybenzyl)-N-( l-methyl-2-
pyridinemethylene) hydroxylamine chloride. 
0-(3,3-Diphenylpropyl)-N-(l-methyl-2-pyridinemethy-
lene) hydroxylamine chloride. 
0-Benzy 1-N-( 3-hydroxy-1-methy 1-2-pyridinemethy-
lene) hydroxylamine chloride (lb). 
O-(p-Methoxybenzyl)-N-(l,6-dimethyl-3-hydroxy-2-
50 pyridinemethylene) hydroxylamine chloride. 
0-(p-Dimethylaminocarbonyloxy benzyl)-N-( 1,6-
dimethyl-3-hydroxy-2-pyridinemethylene) hydroxy-
lamine chloride. 
0-(p-Propylaminocarbonyl benzyl)-N-(l,6-dimethyl-3-
55 hydroxy-2-pyridinemethylene) hydroxylamine chlo-
ride. 
0-Benzyl-N-[3-(N' ,N' -dimethylcarbamoyl)hydroxy-1-
methyl-2-pyridinemethylene]hydroxylamine chloride 
(2a). 
60 0-[2-(l-Methyl-1-piperidinium)ethyl]-N-[3-(N',N'- . 
dimethylcarbamoyl)hydroxy- l-methyl-2-pyridineme-. 
thylene]hydroxylamine dichloride. 
0-[2-(Trimethylammonium)ethyl)-N-[3-(N' ,N'-dime-
thylcarbamoyl)h ydroxy-1-meth y 1-2-pyridineme-
65 thylene]hydroxylamine dichloride. 
0-Benzyl-N-[3-(N' ,N' -diethylcarbamoyl)hydroxy-1-
methyl-2-pyridinemethylene ]hydroxylamine chlo-
ride. 
9 
5,180,831 
O-Benzyl-N-[3-(N',N'-difluoroethylcarbamoyl)hy-
droxy-1-methyl-2-pyridinemethylene)hydroxylamine 
chloride. 
10 
N-[5-(N',N'-Dimethylcarbamoyl)hydroxy-1-methyl-2-
pyridinemethylene]hydroxylamine chloride (2d). 
N-[3-(N' ,N' -Dimethylcarbamoyl)hydroxy-1-methyl-2-
pyridinemethylene ]hydroxylamine chloride. O-Diphenylmethyl-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine iodide. 
0-Benzyl-N-[3-(N' ,N' -dimethylcarbamoyl)hydroxy-
1,6-dimethy 1-2-pyridinemethy Jene )hydroxy !amine 
chloride. 
5 N-[3-(N',N' -Dimethylcarbamoyl)hydroxy-1,6-dimeth-
yl-2-pyridinemethylene]hydroxylamine chloride. 
0-Benzyl-N-[3-(N' ,N' -diethylcarbamoyl)hydroxy-1, 6-
dimethyl-2-pyridinemethylene ]hydroxylamine chlo- IO 
ride. 
O-Benzyl-N-[3-(N',N'-difluoroethylcarbamoyl)hy-
droxy-1,6-dimethy 1-2-pyridinemethylene )h ydroxyla-
mine chloride. 
0-(Diphenylmethyl)-N-[3-(N' ,N' -dimethylcarbamoyl)- 15 
hydroxy-1-methy 1-2-pyridinemethy Jene )hydroxy !a-
mine chloride (2b). 
0-( 1-Naphtylmethyl)-N-(5-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride. 
0-(2-Methyl-1-naphtylmethyl)-N-(5-hydroxy-1-meth-
yl-2-pyridinemethylene) hydroxylamine chloride. 
0-(2,3,4-Trimethoxybenzyl)-N-(5-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride. 
0-(3,3-Diphenylpropyl)-N-(5-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride. 
0-Methy 1-N-( 5-hydroxy-1-methy 1-2-pyridinemethy-
lene) hydroxylamine chloride. 
0-(p-Chlorobenzy 1)-N-( 5-hydroxy-1-methyl-2-
pyridinemethy lene) hydroxylamine chloride. O-(Diphenylmethyl)-N-[3-(N'-isopropylcarbamoyl)hy-droxy-1-methy 1-2-pyridinemethy Jene )hydroxylamine 
chloride. 
0-(Diphenylmethyl)-N-[3-[N' -(2-fluoroethyl)car-
bamoy l)hydroxy-1-methy 1-2-pyridinemethy Jene )hy-
droxy !amine chloride. 
O-(p-Cyanobenzyl)-N-(5-hydroxy-J-methyl-2-
20 pyridinemethylene) hydroxylamine chloride. 
O-(Diphenylmethyl)-N-[3-(N',N'-dimethylcarbamoyl)-
hydroxy-1,6-dimethyl-2-pyridinemethylene )hydrox- 25 
ylamine chloride. 
0-(2-Hydroxy-4-nitro benzyJ).N-(5-hydroxy-1-methyl-
2-pyridinemethylene) hydroxylamine chloride. 
0-(p-Carboxy benzyl)-N-(5-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride. 
O-(p-Methoxybenzyl)-N-(5-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride. 
0-(p-Dimethy laminocarbonyloxy benzy I )-N-( 5-
hydrox y-1-meth y 1-2-pyridinemeth y lene) hydroxy-
0-(Diphenylmethyl)-N-[ l ,6-dimethyl-3-(N' -isopropyl-
carbamoyl)hydroxy-2-pyridinemethylene ]hydroxyla-
mine chloride. 
0-(Diphenylmethy I)-N-[3-[N' -(2-fl uoroeth y l)car-
bamoy l)h ydroxy-1,6-dimeth y 1-2-pyridinemeth y Jene)-
hydrox ylamine chloride. 
0-(p-Methoxybenzyl)-N-[3-(N',N' -dimethylcar-
bamoyl)hydroxy-1-methyl-2-pyridinemethylene )hy-
droxylamine chloride (2c). 
30 !amine chloride. 
0-(p-Propylaminocarbonyl benzyl)-N-(5-hydroxy-1-
35 
0-(p-Methoxybenzyl )-N-[3-(N ', N' -dimeth y Jcar-
bamoyl)h ydroxy-1-eth y 1-2-pyridinemeth y Jene ]h y-
drox y lamine chloride. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar-
bamoyl)hydroxy- l-benzyl-2-pyridinemethylene )hy- 40 
droxylamine bromide. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar-
methyl-2-pyridinemethylene) hydroxylamine chlo-
ride. 
0-(p-Ethoxycarbonyl benzyl)-N-(5-hydroxy-1-methyl-
2-pyridinemethylene) hydroxylamine chloride. 
0-Benzyl-N-[5-(N' ,N' -dimethylcarbamoyl)hydroxy-1-
methyl-2-pyridinemethylene]hydroxylamine chlo-
ride. 
0-Benzyl-N-[5-(N' ,N' -diethylcarbamoyl)hydroxy- l-
methyl-2-pyridinemethylene ]hydroxylamine chlo-
ride. 
O-Benzyl-N-[5-(N',N'-difluoroethylcarbamoyl)hy-
droxy-1-methyl-2-pyridinemeth y Jene ]hydroxy !amine 
chloride. 
bamoy l)hydroxy- l ,6-dimethyl-2-pyridinemethylene )-
hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar-
bamoy I )h ydroxy-1-ethyl-6-methy 1-2-pyridineme-
thylene )hydroxy lamine chloride. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar-
45 O-(Diphenylmethyl)-N-[5-(N'-isopropylcarbamoyl)hy-
droxy-1-methyl-2-pyridinemethylene ]hydroxylamine 
chloride. 
bamoy l)hydroxy-1-benzyl-6-methyl-2-pyridineme-
thylene ]hydroxylamine bromide. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethy lcar-
bamoy 1)hydroxy-1-(1-naphtylmethyl)-2-pyridineme-
thylene ]hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar-
bamoyl)hydroxy-1-(2-methyl-1-naphtylmethyl)-2-
pyridinemethylene )hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar-
bamoy l)hydroxy-1-dipheny lmethy 1-2-pyridineme-
thy lene )hydroxy lamine chloride. 
50 
55 
0-(p-Methoxybenzyl)-N-[3-(N',N'-dimethylcar- 60 
bamoyl)hydroxy-1-(2-hydroxy-4-nitro benzyl)-2-
pyridinemethylene )hydroxy !amine chloride. 
0-(p~ Methoxybenzy 1)-N-[3-(N' ,N' -dimethy lcar-
bamoy l)hydroxy-1-(p-carboxy benzyl)-2-pyridineme-
thylene ]hydroxylamine chloride. 
0-(p-Methoxybenzy 1)-N-[3-(N' ,N' -dimethylcar-
bamoy I )hydrox y-1-(p-cyanobenzyl)-2-pyridineme-
thy lene )hydroxy lamine chloride. 
65 
O-(Diphenylmethyl)-N-[5-[N'-(2-fluoroethyl)car-
bamoy l]hydroxy-1-methyl-2-pyridinemethy Jene )h y-
droxylamine chloride. 
O-(p-Methoxybenzyl)-N-[5-(N',N'-dimethylcar-
bamoyl)hydroxy-1-methyl-2-pyridinemethylene ]hy-
droxylamine chloride. 
0-(p-Methoxybenzyl)-N-[ 5-(N' ,N'-dime th ylcar-
bamoy l)hydroxy-1-ethy 1-2-pyridinemethy Jene ]hy-
droxy !amine chloride. 
0-(p-Methoxybenzyl)-N-[ 5-(N' ,N' -dimethylcar-
bamoy l)hydroxy-1-benzyl-2-pyridinemethy Jene )hy-
droxy !amine bromide. 
0-(p-Methoxybenzyl)-N-[ 5-(N' ,N' -dimethylcar-
bamoyl)hydroxy-1-( 1-naphty !methyl )-2-pyridineme-
thy lene ]hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N-[5-(N' ,N' -dimethylcar-
bamoyl)hydroxy-1-(2-methyl-1-naphtylmethyl)-2-
pyridinemethylene]hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N-[5-(N',N'-dimethylcar-
bamoyl)hydroxy-1-diphenylmethyl-2-pyridineme-
thylene]hydroxylamine chloride. 
11 
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0-(p-Methoxybenzyl)-N-[ 5-(N' ,N' -dimethylcar-
bamoyl)hydroxy-1-(2-hydroxy-4-nitro benzyl)-2-
pyridinemethylene]hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N-[5-(N' ,N' -dimethylcar-
bamoyl)hydroxy-1-(p-carboxy benzyl)-2-pyridineme-
thylene]hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N-[5-(N',N'-dimethylcar-
bamoyl)h ydroxy-1-(p-cyanobenzy I )-2-pyridineme-
thy lene ]hydroxy lamine chloride. 
O-Benzyl-N-(l-benzyl-3-hydroxy-2-pyridinemethy-
lene) hydroxylamine bromide. 
O-Benzyl-N-(l-benzyl-5-hydroxy-2-pyridinemethy-
lene) hydroxylamine bromide. 
2-[[ (Aminocarbony l)hydrazono ]meth y 1)-3-hydroxy-1-
meth y I pyridinium chloride (3a). 
2-[[ (Aminocarbony l)hydrazono ]meth y 1)-5-hydroxy-1-
methy I pyridinium chloride. 
2-[[(Aminothiocarbonyl)hydrazono]methyl)-3-
hydroxy-1-methyl pyridinium chloride. 
2-[[(Aminothiocarbonyi)hydrazono]methyl)-5-
hydroxy-1-methyl pyridinium chloride. 
2-Hydrazonomethyl-3-hydroxy-1-methyl pyridinium 
chloride. 
12 
2-[[(N,N-Dimethylaminothiocarbonyl)hydrazono]me-
thyl)3-hydroxy-1-methyl pyridinium chloride. 
2-[[ (N-Ethy Jaminothiocarbony I )hydrazono ]me thy 1)-3-
hydroxy-1-methy l pyridinium chloride. 
5 3-Hydroxy-l-methyl-2-[[(N-naphtylaminocarbonyl)hy-
drazono ]methyl]pyridinium chloride. 
2-[[[N-( 1-Chloro-2-naphtyl)amino 
drazono ]methyl)-3-hydroxy-1-methyl 
chloride. 
carbonyl]hy-
pyridinium 
10 5-Hydroxy-1-methyl-2-[[(N-phenylaminothiocar-
bony l)hydrazono ]methyl]pyridinium chloride. 
2-[[(N,N-Diphenylaminocarbonyl)hydrazono]methyl)-
5-hydroxy-1-methyl pyridinium chloride. 
2-[[(N,N-Dimethylaminothiocarbonyl)hydrazono]me-
15 thyl)-5-hydroxy-1-methyl pyridinium chloride. 
2-[[(N-Ethylaminothiocarbonyl)hydrazono]methyl)-5-
hydroxy-1-methyl pyridinium chloride. 
5-H ydroxy-1-methyl-2-[[ (N-naphtylaminocarbonyl)hy-
drazono ]methyl]pyridinium chloride. 
20 2-[[[N-(l-Chloro-2-naphtyl)amino 
drazono ]methy 1)-5-hydroxy-1-methyl 
carbonyl)hy-
pyridinium 
2-Hydrazonomethyl-3-hydroxy-1,6-dimethyl 
ium chloride. 
chloride. 
1-Methyl-2-[[(N-phenylaminocarbonyl)hydrazono]me-
thyl]pyridinium chloride (3d). 
pyridin- 25 2-[[(Aminocarbonyl)hydrazono]methyl)-3-(N,N-dime-
2-Hydrazonomethyl-5-hydroxy- l-methyl pyridinium 
chloride. 
1-Methy 1-2-(3-hydroxy-1-methyl-2-pyridinemethy Jene) 
hydrazine chloride. 
1-Methyl-1-phenyl-2-(3-hydroxy- l-methyl-2-
pyridinemethylene) hydrazine chloride. 
l, l-Diphenyl-2-(3-hydroxy-1-methyl-2-pyridinemethy-
Jene) hydrazine chloride. 
l-(2,4-Dinitrophenyl)-2-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydrazine chloride. 
1-Naphtyl-2-(3-hydroxy- l-methyl-2-pyridinemethy-
lene) hydrazine chloride. 
1-Methyl-2-(5-hydroxy-1-methyl-2-pyridinemethylene) 
hydrazine chloride. 
1-Methyl-1-phenyl-2-(5-hydroxy- l-methyl-2-
pyridinemethylene) hydrazine chloride. 
l, l-Diphenyl-2-(5-hydroxy-1-methyl-2-pyridinemethy-
lene) hydrazine chloride. 
1-(2,4-Dinitrophen y 1)-2-( 5-hydroxy-1-methy 1-2-
pyridinemeth y lene )'hydrazine chloride. 
1-Naph ty 1-2-( 5-hydroxy-1-methy 1-2-pyridinemeth y-
lene) hydrazine chloride. 
1Methy1-2-( 1,6-dimeth y 1-3-hydroxy-2-pyridinemeth y-
lene) hydrazine chloride. 
1-Methyl- l-phenyl-2-( l ,6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydrazine chloride. 
1, 1-Diphenyl-2-( l ,6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydrazine chloride. 
3-H ydroxy- l-methyl-2-[[ (N-phen y laminocarbony l)hy-
drazono ]methy l]pyridinium chloride (3b). 
l,6-Dimethyl-3-hydroxy-2-[[(N-phenylaminocarbonyl)-
hydrazono ]methyl]pyridinium chloride. 
5-Hydroxy-1-methy 1-2-[[ (N-phenylaminocarbon yl)hy-
drazono ]methyl)pyridinium chloride. 
3-Hydroxy-1-methy 1-2-[[ (N-pheny laminothiocar-
bonyl)h ydrazono ]methyl]pyridinium chloride. 
2-[[(N,N-Diphenylaminocarbonyl)hydrazono]methyl)-
3-hydroxy-l-methyl pyridinium chloride. 
l,6-Dimethyl-3-hydroxy-2-[[(N-phenylaminothiocar-
bonyl)hydrazono]methyl)pyridinium chloride. 
l,6-Dimethyl-2-[[(N,N -diphenylaminocarbonyl)hy-
drazono]methyl)-3-hydroxy pyridinium chloride. 
thylcarbamoyl)hydroxy-1-methyl pyridinium chlo-
ride (4a). 
2-[[(Aminocarbonyl)hydrazono]methyl)-3-(N,N-dime-
thylcarbamoyl)hydroxy- I ,6-dimethyl pyridinium 
30 chloride. 
2-[[ (Aminocarbon y l )hydrazono ]methyl)-5-(N ,N-dime-
thy lcarbamoy l )hydroxy-1-meth y l pyridinium chlo-
ride 
3-(N ,N-Dimethy lcarbamoyl)hydroxy-1-methy 1-2-[[ (N-
35 phenylaminocarbonyl) hydrazono]methyl]-
pyridinium chloride (4b). 
5-(N ,N-Dimethy Jcarbamoyl)hydroxy-1-methy 1-2-[[ (N-
phen y laminocarbonyl) hydrazono]methyl)-
pyridinium chloride. 
40 2-(3-Hydroxy-1-methyl-2-pyridinemethylene )-1-[2-( 1-
pyridinium)acetyl)hydrazine dichloride (Sa). 
2-( l ,6-Dimethyl-3-hydroxy-2-pyridinemethylene )-1-[2-
(l-pyridinium)acetyl]hydrazine dichloride. 
2-(5-Hydroxy-1-methyl-2-pyridinemethylene)-1-[2-( 1-
45 pyridinium)acetyl]hydrazine dichloride. 
2-(3-Hydroxy-l-methyl-2-pyridinemethylene )-1-[2-
(trimethylammonium)acetyl)hydrazine dichloride. 
1-[2-( 4-Chloro- l-pyridinium)acetyl)-2-(3-hydroxy- l-
methyl-2-pyridinemethylene) hydrazine dichloride. 
50 2-(1,6-Dimethyl-3-hydroxy-2-pyridinemethylene)-l-[2-
(trimethylammonium)acetyl]hydrazine dichloride. 
2-( l ,6-Dimethyl-3-hydroxy-2-pyridinemeth ylene )-1-[2-
( 4-chloro-1-pyridinium)acetyl]hydrazine dichloride. 
1-[2-(3-Carboxy-1-isoquinolinium)acetyl)-2-(3-hydroxy-
55 1-methyl-2-pyridinemethylene) hydrazine dichloride. 
1-[2-(2-Carboxy-4-methoxy-1-quinolinium )acety 1)-2-( 3-
hydroxy- l-methyl-2-pyridinemethylene) hydrazine 
dichloride. 
2-(3-Hydroxy-1-methyl-2-pyridinemethylene )- l-[2-(3-
60 hydroxy-1-pyridinium)acetyl]hydrazine dichloride. 
2-(3-Hydroxy-1-methyl-2-pyridinemethylene)- l-[2-( l-
methyl-1-piperidinium )acety l]hydrazine dichloride. 
2-(5-Hydroxy-1-methyl-2-pyridinemethylene )-1-[2-
(trimethylammonium)acetyl)hydrazine dichloride. 
65 1-[2-( 4-Chloro-1-pyridinium)acetyl)-2-(5-hydroxy- l-
methyl-2-pyridinemethylene) hydrazine dichloride. 
1-[2-(3-Carboxy- l-isoquinolinium)acety 1)-2-( 5-hydrox y-
l-methyl-2-pyridinemethy lene) hydrazine dichloride. 
5,180,831 
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l-[2-(2-Carboxy-4-methoxy- l-quinolinium)acetyl]-2-(S-
hydroxy~ l-methyl-2-pyridinemethylene) hydrazine 
dichloride. 
2-(S-Hydroxy- l-methyl-2-pyridinemethylene )-1-[2-(3-
hydroxy- l-pyridinium)acetyl]hydrazine dichloride. 5 
2-(S-Hydroxy- l-methyl-2-pyridinemethylene )-1-[2-( l-
methyl-1-piperidinium)acetyl]hydrazine dichloride. 
2-(1-Methyl-2-pyridinemethylene )-1-[2-( 1-pyridinium-
)acetyl]hydrazine dichloride (Sb). 
0-Benzyl-N-( I ,6-dimethyl-3-hydroxy-2-pyridinemethy- 10 
lene) hydroxylamine chloride. 
It has been found that the novel pyridinium com-
pounds of this invention are good acetylcholinesterase 
inhibitors in vitro as shown in 'Tables I and II. The 
pyridinium compounds also have good activity in vivo 15 
as prophylactics and antidotes against nerve agent poi-
soning as shown in Tables III-VI. 
Competitive Inhibition of Acetylcholinesterase. The 
reversible inhibition studies on electric eel and human 
erythrocyte AChE were performed at 2S 0 ±J° C. in pH 20 
7 .6, 0.1 M phosphate buffer containing 4% ethanol using 
S-acetyl thiocholine as a substrate (Ellman, G. L., 
Courtney, D., Andres, V., and Featherstone, R. M., 
Biochem. Pharmacol. 1961, 7, 88). For analysis of AChE 
inhibitory potency, electric eel AChE was dissolved in 25 
buffer. Human erythrocyte AChE was dissolved in a 
0.0IM borate buffer (pH 10.2) containing O.Ql % prote-
ase free bovine serum albumin. S,S'-Dithiobis(2-
nitrobenzoic acid) (DTNB) and S-acetylthiocholine 
were prepared in phosphate buffer. All inhibitor solu- 30 
ti:ms were also dissolved in phosphate buffer; some 
: quired the addition of 95% ethanol. Increasing absor-
bance during substrate hydrolysis was monitored on a 
Varian DMS-90 spectrometer. Duplicate studies were 
performed on separate days using fresh solutions. No 35 
time dependent inhibition was observed over a period 
of at least one hour. Using three different substrate 
concentrations and four inhibitor concentrations, a 
Dixon plot (I/activity vs. inhibitor cone.) was made 
and the K1values determined. The K1value is the disso- 40 
ciation constant of the enzyme-inhibitor complex. In-
hibitors with lower K1 values are more potent. In the 
case of poor inhibitors an IC50 was determined by plot-
ting AChE activity vs inhibitor concentration. Only 
values between 10% and 90% inhibition were used. The 45 
exact procedure is as follows. 
First, 20 µ.L of S-acetylthiocholine (0.07SM) and 100 
µ.L of DTNB (0.1 OM) were mixed together with phos-
phate buffer. Inhibitor was then added and the solution 
mixed well. Next, SO µ.L of electric eel AChE (1.S 50 
units/mL) was added and the solution mixed again. 
With human enzyme, 20 µ.L of a 2 units/mL stock solu-
tion was added. Increasing absorbance was monitored 
at 412 nm. Controls were used for each run in the case 
of inhibitors that absorb highly at 412 nm. Hydrolysis 55 
rates of all inhibitors were negligible. Total volume and 
organic solvent, if any, was kept constant. 
Aldoximes (la,b,d,e) showed pure competitive inhibi-
tion of AChE whereas the semicarbazones (3a,b, 4b) 
and acyl hydrazones (Sa, Sb) showed mixed-type inhibi- 60 
tion of AChE (linear, noncompetitive). Results are sum-
marized in Table I. 
The 3-hydroxy substituted aldoximes did not inhibit 
either enzyme well, but did show some selectively for 
the electric eel enzyme. The 3-hydroxy derivative of 65 
2-PAM was also tested and did not inhibit either en-
zyme at concentrations up to I mM. Addition of a ben-
zyl group to the aldoxime of 3-hydroxy-2-PAM (lb) 
14 
improves binding and lb has an ICso of SOO µ.M with 
electric eel AChE. The methylaldoxime le did not 
inhibit either enzyme at concentrations up to I mM. 
Without the 3-hydroxy substituent, tighter binding oc-
curs and K1values of 40 µ.Mand 100 µ.M were observed 
with eel and human enzymes respectively for the benzyl 
aldoxime la. 
The bis-pyridinium acyl hydrazones Sa-b were the 
tightest binding reversible inhibitors with Sa having K1 
values of 10 and 20 µ.M with electric eel and human 
erythrocyte AChE, respectively. However, 3-hydroxy 
substitution did not have the same effect on acyl hydra-
zones as with the aldoximes. In this case a 3-hydroxy 
group improved the binding to AChE. The complex 
kinetics of Sb indicate at least two different binding 
modes for this inhibitor. At concentrations up to 7S µ.M, 
Sb acts as a noncompetitive inhibitor. However, at 
higher concentrations, Sb is an uncompetitive inhibitor. 
Only noncompetitive kinetics were observed for Sa. 
All of the semicarbazones (3a,b, 4b) also exhibited 
noncompetitive kinetics. In addition, multiple binding 
was observed and compound 3b had two distinct K1 
values of 30 µ.M and 340 µ.M with electric eel AChE. 
Addition of a phenyl group to give the semicarbazone 
3b resulted in a decrease of the IC50 to 240 µ.M with the 
human enzyme. From the kinetic results, it appears that 
binding in a hydrophobic pocket near the active site is 
the most important interaction for the semicarbazones. 
Compound 4b is the most indicative of this trend. Un-
like all other carbamates, it is not a time dependent 
inhibitor indicating that its position near the active site 
serine is not equivalent to that occupied by the aldox-
imes 2a-c in the E.I complex. Also, the 3-hydroxyl 
group does not negatively influence binding as with the 
3-hydroxy aldoximes which further indicates that bind-
ing of the semicarbazones is different from the aldox-
imes. 
Irreversible Inhibition of Acetylcholinesterase. The 
irreversible inhibition studies of electric eel and human 
erythrocyte AChE were performed at 2S 0 ±I 0 C. in 
O.IM phosphate buffer. Inhibitor and enzyme were 
incubated in a buffer solution of 1.0 mL total volume 
and 100 µ.L aliquots were taken at I min intervals. The 
aliquots were added to freshly prepared assay solutions 
containing 20 µ.L of S-acetylthiocholine, 100 µ.L of 
DTNB, and 2280 µ.L of buffer. Increasing absorbance 
was monitored at 412 nm. Pseudo first order inhibition 
constants were determined by measuring the enzymatic 
activity of acetylcholinesterase after incubating the 
enzyme with inhibitor for various time periods. Second 
order inhibition rate constants kobsl[I] are reported in 
Table II. Inhibitors with higher kobsl[I] values are more 
potent. Half-lives for inactivation ranged from 10.8 min 
for 4a to about 9 sec for 2c. The kobsl[I] for 2c was 
estimated at > 110,000M- ls-1 because its rapid inacti-
vation of AChE made it difficult to accurately deter-
mine its inhibitory potency. Compounds 2a-c are novel 
analogs of 2-PAM that also incorporate a dimethylcar-
bamyl substituent that reacts covalently with AChE. 
Compounds 2a and 2c have greater anti AChE activity 
in vitro with human AChE than either pyridostigmine 
or physostigmine. A notable selectivity for the human 
enzyme was observed for all of the carbamates. The 
semicarbazone 4a inactivated AChE very slowly. In 
contrast, the phenyl substituted semicarbazone carba-
mate 4b was not a time dependent inhibitor of AChE 
over a period of l.S hours, unlike all other carbamates 
tested. Both compounds have similar K1 values with 
5,180,831 
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electric eel AChE: 4a has a K1of 100 µMand 4b has a 
16 
Carbamate derh:atives 2a-2c and carbamate semicar-
bazone 4b showed excellent activity in the oral pretreat-
ment studies. They afforded 80-100 survival rates at 120 
min prior to nerve agent challenge while pyridostig-
K1 of 8S µM. A K1 for the human enzyme could not be 
determined for 4a because of its rapid inactivation of 
AChE at inhibitor concentrations exceeding IO times 
the enzyme concentration. 5 mine alone allowed no survival. In contrast to its good 
activity in the i.m. studies, bis-pyridinium acyl hydra-
zone Sa was not good as an oral pretreatment agent. 
This may be due to fast clearance from the animal re-
Animal Studies-Pretreatment Activity. All animal 
studies were carried out at Battelle, Inc., in Columbus, 
OH. The results of in vivo mouse evaluations against 
GD for the compounds tested as intramuscular (i.m.) or 
oral pretreatment agents are given in Tables III and IV 10 
respectively and were obtained as follows. Male ICR 
mice from Charles River (20 to 30 g average weight) 
were treated with three different doses of the pyridin-
ium test compound i.m. lS or 60 min, or by gavage 30 or 
120 min before challenge with a dose of 2XLDsoofGD 15 
(LDso=98 µg/kg without atropine, LDso= 130 µg/kg 
with 11.2 mg/kg of atropine). The 24 h LDsoofthe test 
compounds administered i.m. or orally were deter-
mined using S-7 dose groups with S animals per dose. 
. ,. 1· d . . 20 As a negative re1erence treatment, sa me was a mm1s-
tered instead of the test compound. As a positive con-
trol for survival, pyridostigmine (0.1 mg/kg, i.m.; 0. 82 
mg/kg, orally) was administered to a separate group of 
animals. All pretreatment groups received atropine 25 
sulfate (11.2 mg/kg) and 2-PAM (2S mg/kg) i.m. ex-
actly 10 seconds after GD challenge, using a total dose 
volume of O.S mL/kg body weight. All animals were 
allocated to pretreatment cells in a randomized block 
design. Groups of ten mice were used in each experi- 30 
ment and survivors in each group were noted after 24 h. 
The 24-hour survival of animals pretreated with each 
dose of the pyridinium test compound was compared 
with the 24-hour survival observed in the negative ref-
erence pretreatment group. A survival difference of at 35 
least four is required to identify improved efficacy of 
the candidate over that observed with the negative 
reference pretreatment. 
Compounds 2a-d, 4a-b, Sa-b were excellent pretreat-
ment agents, affording significant protection against a 40 
dose of 2 x LDso of GD. In all cases saline solution was 
used as the baseline standard (all mice die) and pyrido-
stigmine as the positive control for survival (80-100% 
of the mice survive). 
Carbamate derivatives 2a-2d showed 70 to 90% sur- 45 
viva! rates at selected doses. After lS min pretreatment 
with compound 2a, 2b, or 2d 90% of mice survive a 
challenge of 2 X LDso of GD at comparable fractions of 
the LDso's for these compounds (1/SS LDso of 2a, 1/72 
LDso of 2b, 1/67 LDso of 2d). On the other hand, com- 50 
pound 2c afforded a 70% survival rate under the same 
conditions but at a 1/16, 700 fraction of its LDso. Carba-
mate semicarbazones 4a and 4b and the acyl hydrazones 
Sa and Sb were also very good i.m. pretreatment agents. 
Carbamate semicarbazone 4a was exceptionally good as 55 
a pretreatment agent. Acyl hydrazones Sa and Sb were 
also excellent pretreatment agents but their effective 
doses were much closer to their toxic doses than was 
the case with 4a. Except for 4a, all remaining pretreat-
ment agents were more effective when given lSmin 60 
prior to Soman challenge. The decrease in efficacy at 60 
min may be due to transformation of the drugs to inac-
tive metabolites and/or clearance from the animal. It 
was most noticeable for acyl hydrazones Sa and Sb, 
which was doubly charged and can be excreted more 65 
rapidly. All seven pretreatment agents offered compa-
rable or better protection against GD than the positive 
control, pyridostigmine. 
quiring higher doses that approach the toxic dose. 
Oximes 1 a-1 f and semicarbazones 3b, 3c and 3d were 
inactive in the i.m. pretreatment assay. In the case of 
substituted oxime derivatives a 3-hydroxy substituent 
significantly reduces drug toxicity (la> lb). On the 
other hand increasing the steric bulk of the oxyimino 
substituent increases drug toxicity (lb> le). 
Animal Studies-Reactivator Activity. The results of 
in vivo mouse evaluations against GD and GA for the 
compounds tested as OP reactivators are given in Ta-
bles V and VI and were obtained as follows. Male ICR 
mice from Charles River (20 to 30 g average weight) 
were treated with the pyridinium test compound at 
three different doses administered i.m. 10 seconds after 
challenge with 2 X LDso of GD or GA (aqueous solu-
tion containing 0.9% NaCl). The test compound was 
always given simultaneously with atropine sulfate (11.2 
mg/kg). As a negative reference treatment group, atro-
pine sulfate (11.2 mg/kg) and 2-PAM (2S mg/kg) were 
given without the pyridinium test compound (no mice 
survive). As a positive control for survival, HI-6 (9.6 
mg/kg) was administered with atropine sulfate (11.2 
mg/kg) to a separate group of animals. All injections 
were administered i.m. using a dose volume of O.S 
mL/kg body weight. All animals were allocated to 
treatment cells in a randomized block design. Groups of 
ten mice were used in each experiment and survivors in 
each group were noted after 24 h. The 24-hour survival 
of animals injected with each dose of test compound 
was compared to the 24-hour survival observed in the 
negative reference treatment cell. A survival difference 
of at least four is required to identify improved efficacy 
of the candidate over that observed with the reference 
treatment. An alternate procedure used on some com-
pounds was the adjunct efficacy test: the pyridinium test 
compound was always given simultaneously with atro-
pine sulfate (11.2 mg/kg) and 2-PAM (2S mg/kg). The 
rest of the procedure is as described above. 
Carbamate oxime derivatives 2a, 2b, semicarbazone 
3a, carbamate semicarbazone 4b and bis-pyridinium 
acyl hydrazones Sa and Sb showed significant activity 
as GD reactivators (Table V). The last two also showed 
significant activity as GA reactivators (Table VI). 
2-PAM was used as the baseline standard while the 
positive control used HI-6 as the reactivator. Carba-
mate oximes 2a and 2b afforded SO% and 70% survival 
rates respectively at a dose 1/16 of their LDso's. They 
were also the most toxic of the five derivatives that 
showed activity as OP reactivators. The greater inhibi-
tion of AChE displayed by 2a compared to 2b is 
matched by its greater toxicity. A 62 fold increase in 
kobsl[I] accompanied by a 44 fold increase in toxicity 
indicates that in the case of irreversible inhibitors a. 
compromise must be reached between the degree of 
inhibition that affords protection from the OP agent and 
that which prevents the .enzyme from performing its 
physiological role. It is noteworthy that 2a and 2b must 
be acting as prodrugs of the actual OP reactivator since 
they do not possess a nucleophile themselves that can 
displace the OP from the active site of AChE. In the 
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semicarbazone series, a 3-hydroxy substituent increases 
in vivo activity (3a> >3c). Semicarbazone 3a afforded 
70% survival rate at 1/2S of its LDso when given JO 
seconds after a challenge of 2 X LDso of Soman. Semi-
carbazone 3a was also an excellent reactivator when 5 
tested in the adjunct assay: it afforded 90% survival rate 
when administered along with 2-PAM (2S mg/kg) 10 
seconds after Soman challenge. This combination of 
drugs was more effective than HI-6 in counteracting 
Soman intoxication. Carbamate semicarbazone 4b af- 10 
forded SO% survival rate at 1/16 of its LDsowhen given 
10 sec after a challenge of 2 X LDso of Soman. Bis-
pyridinium acyl hydrazone Sa was· an excellent GD 
reactivator. It afforded 90% survival rate at a dose of73 
mmol/kg (approx. g LDso) when given 10 seconds after 15 
Soman challenge. 
Two hydroxy 2-PAM derivatives (lf, lg) were pre-
pared and tested for comparison with 2-PAM and with 
the other substituted oxime derivatives reported in this 
study. The parent 2-PAM is not an effective reactivator 20 
against Soman due to rapid "aging" of the inhibited 
AChE. Adding a hydroxy substituent to the 3 or S 
position of 2-PAM resulted in no improvement in reac-
tivating ability concurrent with a small increase in tox-
icity. In addition, these derivatives were not signifi- 25 
cantly better than 2-PAM in the pretreatment assay. 
The carbamate of S-hydroxy-2-PAM chloride, com-
pound 2d, incorporates the structural features of pyri-
dostigmine and 2-PAM. It afforded 90% survival rate at 
a dose 1/67 of its LDso when given lS or 60 minutes 30 
prior to Soman challenge. 
Summary-Animal Studies. The in vivo activity de-
scribed herein for some of the novel pyridinium com-
pounds of this invention can be summarized as follows: 
eight compounds (2a-2d, 4a, 4b, Sa, Sb) were effective 35 
i.m. prophylactics against GD; four compounds (2a-2c, 
4b) were effective oral prophylactics against GD; six 
compounds (2a, 2b, 3a, 4b, Sa, Sb) were good in vivo 
reactivators against GD; two compounds (Sa, Sb) were 
good in vivo reactivators against GA; five compounds 40 
(2a, 2b, 4b, Sa, Sb) were both excellent prophylactics 
and good reactivators against GD. Compounds 4a and 
3a form a set in which an excellent prophylactic (4a) is 
transformed by AChE into a good OP reactivator (3a). 
Structural requirements for prophylactic activity are a 45 
carbamate moiety and/or a second quaternary center. 
Since carbamates may act as prodrugs for the actual 
reactivators (i.e. 3a and 4a), the latter structural require-
ments also apply for AChE reactivators in addition to 
semicarbazones having a free OH group in the pyridine 50 
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suspensions, dispersible powders or granules, emulsions, 
hard or soft capsules or syrups or elixirs. Dosage levels 
of the order to 0.2 mg to 140 mg per kilogram of body 
weight per day are useful in the treatment of above-
indicated conditions (10 mg to 7 gms per patient per 
day). The amount of active ingredient that may be com-
bined with carrier materials to produce 'a single dosage 
form will vary depending upon the host treated and the 
particular mode of administration. 
For injection, the therapeutic amount of pyridinium 
compounds of the present invention will normally be in 
the dosage range from 0.2 mg to 140 mg/kg of body 
weight. Administration is made by intravenous, intra-
muscular or subcutaneous injection. Accordingly, phar-
maceutical compositions for parenteral administration 
will contain in a single dosage form about 10 mg to 7 
gms of pyridinium compound of the present invention. 
In addition to the active ingredient, these pharmaceuti-
cal compositions will usually contain a buffer, e.g. a 
phosphate buffer which keeps the pH in the range from 
3.S to 7 and also sodium chloride, mannitol or sorbitol 
for adjusting the isotonic pressure. 
A composition for tonical application can be formu-
lated as an aqueous solution, lotion, jelly or an oily 
solution or suspention. A composition in the form of an 
aqueous solution is obtained by dissolving the pyridin-
ium compounds of the present invention in aqueous 
buffer solution of pH 4 to 8.S and if desired, adding a 
polymeric binder. An oily formulation for topical appli-
cation is obtained by suspending the pyridinium com-
pounds of the present invention in an oil, optionally 
with the addition of a swelling agent such as aluminium 
stearate and/or a surfactant. 
. Synthetic Methods. All common chemicals and sol-
vents were reagent grade or better. The purity of each 
compound was checked by I H NMR, mass spectros-
copy, thin-layer chromatography (TLC), and elemental 
analysis. Results are consistent with the proposed struc-
tures. Melting points were obtained on a Biichi capillary 
melting point apparatus and are uncorrected. IH NMR 
spectra were recorded with a Varian Gemini 300 MHz 
NMR spectrometer; chemical shifts are reported in 
parts per million (o) from an internal tetramethylsilane 
standard. Mass spectra were recorded on a Varian Mat 
I 12s spectrometer. Elemental analyses were performed 
by Atlantic Microlab in Atlanta, Ga. 3-Hydroxy-2-pyri-
dine carboxaldehyde (Stempel, A. and Buzzi, E. C., J. 
Am. Chem. Soc. 1949, 71, 2969; Ginsburg, S. and Wil-
son, I. B., J. Am. Chem. Soc. 19S7, 79, 481, incorporated 
herein by reference) was prepared from 3-hydroxy-2-
ring. hydroxymethyl pyridine by oxidation using manganese 
Drug Delivery. For the prophylaxis of OP poisoning dioxide (Demerseman, P., Kiffer, D., Debussche, L., 
and for the treatment of OP overdose, Myasthenia Gra- Lion, C., Royer, R., and S.-Roumanou, H., Eur. J. Med. 
vis, senile dementia such as is seen in Alzheimer's and Chem. 1988, 23, 63, incorporated herein by reference). 
adult Down's syndrome patients, high blood pressure, 55 Girard's reagent "P" [1-(carboxymethyl)pyridinium 
glaucoma, and abdominal distension the pyridinium chloride], 4-phenylsemicarbazide, and 3-hydroxy-6-
compounds of the present invention may be adminis- methyl-2-pyridinemethanol were purchased from Ald-
tered orally, topically or parenterally. The term paren- rich Chemical Company. 
teral as used includes subcutaneous injection, intrave- The oxime, hydrazone, semicarbazone and acyl hy-
nous, intramuscular, intrasternal injection or infusion 60 drazone derivatives described herein were prepared 
techniques. The dosage depends primarily on the spe- using standard methodology. Many different 0-sub-, 
cific formulation and on the object of the therapy or stituted hydroxylamines can be prepared by known 
prophylaxis. The amount of the individual doses as well procedures (Grochowski, E. and Jurczak, J., Synthesis 
as the administration is best determined by individually 1976, 682; Schumann, E. L., Heinzelman, R. V., Greig, 
assessing the particular case. 65 M. E., and Veldkamp, W., J. Med. Chem. 1964, 7, 329, 
The pharmaceutical compositions containing the ac- incorporated herein by reference) to afford the various 
tive ingredient may be in a form suitable for oral use, for substituted oximes described herein. Several substituted 
example as tablets, troches, lozenges, aqueous or oily hydrazines are commercially available (i.e. methylhy-
5,180,831 
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drazine, 1, 1-dimethylhydrazine, l, l-diphenylhydrazine, 
from Aldrich Chemical Co.) and others can be synthe-
sized by standard methodology (i.e. Hoffman degrada-
tion of ureas, reduction ofN-nitroso compounds, reduc-
tion of diazonium salts) to afford the hydrazone deriva- 5 
tives described herein. Several substituted semicarba-
zides are commercially available (i.e. 4-phenyl-3-thi-
osemicarbazide, 4,4-diphenylsemicarbazide, 4,4-dimeth-
yl-3-thiosemicarbazide, 4-ethyl-3-thiosemicarbazide) 
and others can be synthesized by standard methodology 10 
(reduction of N-nitro ureas). Commercially available 
Girard's reagent "T" [(carboxymethyl) trimethylammo-
nium chloride hydrazide] can be used instead of Gir-
ard's reagent "P" to obtain 2-(trimethylammonium)a-
cetyl hydrazine derivatives similar to Sa and Sb. Other 15 
hydrazides for the synthesis of various acyl hydrazones 
described herein can be made by known methodology 
(Vogel, A. I., in A Textbook of Practical Organic Chemis-
try; Longman Group Limited: London, 1972; pp. 
976-978, incorporated herein by reference), which in- 20 
volves the reaction between an amine and ethyl chloro-
acetate, followed by reaction with hydrazine hydrate. 
Conversion of the 3 or S-hydroxy moiety into a carba-
mate was accomplished using N,N-dimethylcarbamyl 
chloride. Other N,N-disubstituted carbamates can be 25 
made by reaction between commercially available tri-
phosgene and a disubstituted amine, followed by reac-
tion with the 3 or S-hydroxy pyridine derivative. N-
monosubstituted carbamates can be prepared by reac-
tion of the free 3-0H group on the pyridine ring and any 30 
of numerous isocyanates that are commercially avail-
able. In the case of fluorinated derivatives, the synthesis 
of the appropiate fluoroalkylamine (some are commer-
cially available) is required, followed by reaction with 
phosgene to generate the desired isocyanate. Quaterni- 35 
zation of the pyridine nitrogen was carried out using 
methyl iodide in a sealed glass pressure vessel and was 
followed by anion exchange using a biphasic mixture of 
silver chloride and the methiodide in acetonitrile/wa-
ter. Other salts of the pyridinium compounds described 40 
herein can be made in similar fashion, by methathesis 
involving the silver salt of the desired counterion and 
the methiodide formed in the initial alkylation of the 
pyridine nitrogen. The usefulness of this procedure has 
been studied with 2-PAM derivatives (Kondritzer, A. 45 
A., Ellin, R. I., and Edberg, L. J., J. Pharm. Sci. 1961, 
SO, 109, incorporated herein by reference). 
The following examples are given to illustrate the 
invention and are not intended to limit it in any manner: 
EXAMPLE 1 
Preparation of 
O-Benzyl-N-(l-methyl-2-pyridinemethylene) 
Hydroxylamine Chloride (la) 
O-Benzyl-N-(2-pyridinemethylene) hydroxylamine. 
0-Benzylhydroxylamine hydrochloride (12.77 g, 0.08 
mol) was added to a solution of NaOH (3.2 g, 0.08 mol) 
50 
55 
in 80 mL 1:1 EtOH/H20. Pyridine-2-carbaldehyde (7.6 
mL, 0.08 mo!) was added to this solution and the result- 60 
ing mixture was stirred at room temperature for IO h. 
Excess water was removed under vacuum and the resi-
due was fractionally distilled under reduced pressure 
(14 mm Hg). The product was obtained as a yellow oil 
in the fraction distilling at 8S 0 -90° C. (11.3 g, 67% ). lH 65 
NMR (Me2SO-d6) 8: S.2S (s, 2H), 7.24 (t, lH), 7.32-7.44 
(m, SH), 7.66 (t, IH), 7.78 (d, IH), 8.23 (s, IH), 8.S8 (d, 
IH). 
20 
0-Benzyl-N-( l-methyl-2-pyridinemethxlene )hydrox-
ylamine iodide. Methyl iodide (14.3 mL, 0.23 mol) was 
added to a solution of O-Benzyl-N-(2-pyridinemethy-
lene) hydroxylamine (11.3 g, O.OS mol) in 7S mL of 
acetonitrile. The resulting mixture was heated in a pres-
sure vessel at 6S 0 C. for 24 h. The solvent was removed 
in vacuo and the residue was triturated with acetone to 
afford the product as a light orange solid (17.2 g, 92%), 
m.p. 12S'-7° C. (dee.). lH NMR (Me2SO-d6) 8: 4.36 (s, 
3H), S.38 (s, 2H), 7.36-7.49 (m, SH), 8.09 (t, IH), 8.36 (d, 
IH), 8.SS (t, lH), 8.84 (s, IH), 9.00 (d, IH). 
O-Benzyl-N-(l-methyl-2-pyridinemethylene) hy-
droxylamine chloride. Silver chloride (freshly prepared 
from 14.6 g AgN03 and excess cone. HCl) was added to 
a solution of 16.2 g (O.OS mol) ofO-Benzyl-N-(l-methyl-
2-pyridinemethylene)hydroxylamine iodide in 800 mL 
HiO. The suspension was vigorously stirred with a 
mechanical stirrer for 4 h at room temperature. The 
yellow precipitate was filtered off and the filtrate was 
concentrated to dryness and coevaporated several times 
with acetone. Traces of solvent are removed by evapo-
ration at so· C. in a rotary evaporator at 0.8 mm Hg 
overnight. The yellow solid that remains (11.63 g) is 
recrystallized from EtOH/acetone with scratching to 
obtain 8.1 g (68%) of analytically pure product as beige 
microscopic needles; m.p. 14S' -6° C. (dee.). Anal. 
Calcd. for C14H1sCIN20 x HiO: C, 61.87; H, S.93; N, 
10.31; Cl, 13.0S. Found: C, 61.94; H, S.94; N, 10.31; Cl, 
13.10. lH NMR (Me2SO-d6) 8: 4.38 (s, 3H), S.38 (s, 2H), 
7.36-7.48 (m, SH), 8.09 (t, lH), 8.3S (d, IH), 8.86 (s, lH), 
9.08 (d, IH). 
0-(Diphenylmethyl)-N-(l-methyl-2-pyridinemethy-
lene) hydroxylamine chloride O-(p-chlorobenzyl)-N-(l-
methyl-2-pyridinemethylene) hydroxylamine chloride 
0-(p-methox ybenzy I )-N-( 1-methy 1-2-pyridinemethy-
lene) hydroxylamine chloride 0-(1-naphtylmethyl)-N-
(l-methyl-2-pyridinemethylene) hydroxylamine chlo-
ride 0-(2-methyl-1-naphtylmethyl)-N-( l-methyl-2-
pyridinemethylene) hydroxylamine chloride, 0-(2,3,4-
trimethoxybenzy I)-N-( l-methyl-2-pyridinemethy Jene 
hydroxylamine chloride, and 0-(3,3-diphenylpropyl)-
N-(1-methyl-2-pyridinemethylene) hydroxylamine 
chloride can be made by the same procedure replacing 
0-benzyl hydroxylamine in the above example respec-
tively with 0-(diphenylmethyl) hydroxylamine, 0-(p-
chlorobenzyl) hydroxylamine, 0-(p-methoxybenzy) 
hydroxylamine, 0-(1-naphtylmethyl) hydroxylamine, 
0-(2-methyl-1-naphtylmethyl) hydroxylamine, 0-
(2,3,4-trimethoxybenzyl) hydroxylamine, and 0-(3,3-
diphenylpropyl) hydroxylamine. 
EXAMPLE2 
Preparation of 
0-Benzy 1-N-(3-hydroxy-1-methyl-2-pyridinemeth y-
lene) hydroxylamine chloride (lb) 
O-Benzyl-N-(3-hydroxy-2-pyridinemethylene) hy-
droxylamine. A solution of 0-benzyl hydroxylamine 
was prepared by dissolving 2 g of sodium hydroxide 
(O.OS mo!) and 8 g of 0-benzyl hydroxylamine hydro-. 
chloride (0.0S mo!) in SO mL of SO% ethanol-water. To. 
this solution was added 6.1 S g of 2-formyl-3-hydrox-
ypyridine (O.OS mo!). The mixture was stirred for 3 h at 
room temperature. The precipitate was then filtered and 
air dried to yield 10.3 g (90.3%) of pure product; m.p. 
64°-6S 0 C. lH NMR (CDCl3) 8: 9.72 (s, IH. OH); 8.37 
(s, IH, CH=N); 8.13 (d ofd, J=2H, J=4Hz. IH): 7.33 
(m, 7H); S.17 (s, 2H, CH2). Anal. Calcd. for 
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C13H12N202: C, 68.41; H, 5.30; N, 12.27. Found: C, 
68.34; H, 5.32; N, 12.21. 
O-Benzyl-N-(3-hydroxy-1-methyl-2-pyridinemethy-
lene) hydroxylamine chloride. O-Benzyl-N-(3-hydroxy-
2-pyridinemethylene) hydroxylamine (2.65 g, 11.6 5 
mmol) was placed in a pressure tube together with 7 g 
of methyl iodide and 40 mL of a 2:3 mixture of EtOH/-
water. The reaction mixture was heated at 65' C. for 20 
h and the solvent was then removed in vacuo. The 
residue was triturated with acetone to afford 2.50 g 10 
(58%) of product as greenish crystals; m.p. 247' C. 
(dee.). The methiodide salt (4.90 g, 13.2 mmol) was 
dissolved in 22 mL of a 1: 1 mixture of acetonitrile and 
water and freshly made AgCl was then added (from 4.0 
g AgN03 and excess cone. HCl, washed well with wa- 15 
ter). Additional water (15 mL) was added to this sus-
pension and the resulting mixture was stirred at room 
temperature for 40 min. The silver iodide was removed 
by filtration and the filtrate was conmcentrated to dry-
ness in vacuo to yield a residue that was triturated with 20 
acetone. The solid that resulted was washed well with 
acetone and dried to yield 3.61 g (98%) of product as 
white crystals; m.p. 146' C. IH NMR (DMSO-d6) 8: 
8.58 (d, lH, J =5.0 Hz), 8.55 (s, lH), 8.20 (d, lH, J =7.3 
Hz), 7.90 (d of d, lH), 7.42 (m, SH), 5.34 (s, 2H), 4.27 (s, 25 
3H). Anal. Calcd. for C14H1sN202Cl x H20: C, 56.65; 
H, 5.78; N, 9.43; Cl, 11.94. Found: C, 56.65; H, 5.79; N, 
9.40; Cl, 11.88. 
0-( 1-Naphtylmethyl)N-(3-hydroxy- l-methyl-2-
pyridinemethylene) hydroxylamine chloride, 0-(2- 30 
methyl-1-naphtylmethyl)-N-(3-hydroxy- l-methyl-2-
pyridinemethylene) hydroxylamine chloride, 0-(2,3,4-
trimethoxybenzy 1)-N-(3-hydroxy-1-methy1-2-
pyridinemethylene) hydroxylamine chloride, and 0-
(3,3-diphenylpropyl)-N-(3-hydroxy-l-methyl-2- 35 pyridinemethylene) hydroxylamine chloride can be 
made by the same procedure replacing 0-benzyl hy-
droxylamine in the above example respectively with 
0-(1-naphtylmethyl) hydroxylamine, 0-(2-methyl-l-
na;htylmethyl) hydroxylamine, 0-(2,3,4-trimethoxy- 40 benzyl) hydroxylamine, and 0-(3,3-diphenylpropyl) 
hydroxylamine. 0-( 1-Naphtylmethyl)-N-(5-hydroxy- l-
methyl-2-pyridinemethylene) hydroxylamine chloride, 
0-(2-methyl- l-naphtylmethyl)-N-(5-hydroxy- l-methyl-
2-pyridinemethylene) hydroxylamine chloride, 0- 45 (2, 3,4-trimethoxybenzyl )-N-( 5-h ydroxy- l-methyl-2-
pyridinemethylene) hydroxylamine chloride, and 0-
(3 ,3-dipheny lpropyl )-N-( 5-hydroxy- l-methyl-2-
pyridinemethy lene) hydroxylamine chloride can be 
made by the same procedure substituting 3-hydroxy-2- 50 pyridine carbaldehyde for 2-formyl-5-hydroxy pyri-
dine. 
EXAMPLE 3 
Preparation of 55 O-Methyl-N-(3-hydroxy- l-methyl-2-pyridinemethy-
lene) hydroxylamine chloride (le) 
O-Methyl-N-(3-hydroxy-2-pyridinemethylene) hy-
droxylamine. NaOH (1.62 g, 0.04 mol) was added to a 
solution of methoxyamine hydrochloride (3.4 g, 0.04 60 
mol) in 30 ml of H20. 3-Hydroxy-2-pyridine carboxal-
dehyde (5.0 g, 0.04 mol) was added to the clear solution, 
followed by 15 mL of EtOH. The reaction mixture was 
stirred at room temperature for 15 h and concentrated 
in vacuo to a minimum volume (approx. 5 mL). Water 65 
(15 mL) was added to this residue and the resulting 
solution was extracted with EtOAc (4X20 mL). The 
organic extract was dried (MgS04), filtered and con-
22 
centrated in high vacuum to a yellow oil that crystal-
lizes upons cooling in a bath of isopropanol-dry ice to 
yield 4.83 g (79%) of product as a white solid; m.p. 
186°-7° C. (dee). IH NMR (CDCl3) 8: 9.82 (s, lH); 8.35 
(s, lH); 8.21 (d of d, lH, J = 1.5 Hz, J =4.5 Hz); 7.30 (d 
ofd, lH, J= 1.5 Hz, J=8.5 Hz); 7.19 (d ofd, lH, J=4.5 
Hz, J=8.5 Hz). 
0-Methy l-N-(3-hydroxy-1-methy 1-2-pyridinemethy-
lene) hydroxylamine iodide. Methyl iodide (8.9 mL, 
0.14 mol) was added to a solution of O-methyl-N-(3-
hydroxy-2-pyridinemethylene) hydroxylamine (4.83 g, 
32 mmol) in 20 mL of acetonitrile. The reaction mixture 
was heated in a pressure glass bottle at 70' C. for 20 h 
and then concentrated to dryness in vacuo. The result-
ing yellow solid was triturated with acetone and filtered 
to yield 7.72 g (82%) of product which was used in the 
next step without further purification. 
0-Methy l-N-(3-hydroxy-1-methyl-2-pyridinemethy-
lene) hydroxylamine chloride. The.methiodide obtained 
in the previous step (7.72 g, 26 mmol) was dissolved in 
230 mL of H20. Freshly made AgCl (7.6 g, 53 mmol) 
was added to this solution and the resulting suspension 
was stirred at room temperature for 1.5 h. The reaction 
mixture was filtered and the filtrate was concentrated to 
dryness in vacuo. The white solid that resulted was 
triturated with warm (40' C.) acetone and filtered to 
yield 4.35 g (83%) of product; m.p. 186'-7' C. (dee.). IH 
NMR (DMSO-d6) 8: 8.62 (d, lH, J = 6.0 Hz); 8.48 (s, 
lH); 8.31 (d, lH, J=8.5 Hz); 7.93 (d ofd, lH, J=6.0Hz, 
J = 8.5 Hz). Anal. Calcd. for CsH11N2Cl02: C, 47.41; H, 
5.47; N, 13.83; Cl, 17.50. Found: C, 47.47; H, 5.49; N, 
13.76; Cl, 17.43. 
0-Meth y 1-N-( 5-hydroH-1-methyl-2-pyridinemethy-
lene) hydroxylamine chloride can be made by the same 
procedure replacing 3-hydroxy-2-pyridine aldehyde in 
the above example with 2-formyl-5-hydroxy pyridine. 
0-[2-( 1-Methyl-1-piperidinium]ethyl)-N-(3-hydroxy-1-
methyl-2-pyridinemethylene) hydroxylamine dichlo-
ride and 0-[2-(trimethyl ammonium)ethyl)-N-(3-
hydroxy-l-methyl-2-pyridinemethylene) hydroxylam-
ine dichloride can be made by the same procedure re-
placing methoxyamine in the above example with 0-[2-
( l-piperidine )ethyl]hydroxylamine and 0-[2-(dime-
th y I amino )eth y I ]hydroxy !amine. 
EXAMPLE4 
Preparation 
0-(p-Chlorobenzyl)-N-( 3-hydroxy-1-meth y 1-2-
pyridinemethy lene) hydroxylamine chloride (ld) 
0-(p-Chlorobenzyl)hydroxylamine hydrochloride. 
The hydroxylamine hydrochloride was prepared by 
hydrazinolysis of the corresponding benzyloxyphthali-
mide. The phthalimide (15 g, 0.051 mo!) was dissolved 
in DMF (75 mL) and MeOH (260 mL) and warmed to 
60° C. The solution was treated with hydrazine mono-
hydrate (5. 7 g, 0.11 mol) and allowed to cool to room 
temperature for 3 h. The mixture was acidified to pH 2 
with 2N HCI and filtered. The filtrate was evaporated 
to dryness and treated with 2N NaOH (75 mL). The 
oily product was extracted with ether, and the com-. 
bined ether extracts were washed with H20, dried over 
anhydrous K2C03, and concentrated in vacuo. The 
resulting oil was treated with ethereal hydrogen chlo-
ride to precipitate the product as a white solid. Recrys-
tallization from EtOH gave the pure hydroxylamine 
hydrochloride as shiny white plates (9.5 g, 96%), m.p. 
235' C. [lit. m.p. 245' C.; Schumann, E. L., Heinzelman, 
5,180,831 
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R. V., Greig, M. E., and Veldkamp, W., J. Med Chem. 
1964, 7, 329). IH NMR (CDCl3) d: 7.23(s, 4H); 5.00(s, 
2H). 
0-(p-Cyanobenzyl)hydroxylamine hydrochloride, 
0-(2-Hydroxy-4-nitrobenzyl) hydroxylamine hydro- 5 
chloride, and 0-(p-Carboxy benzyl)hydroxylamine hy-
drochloride can be made by the same procedure replac-
ing p-chlorobenzyloxyphtalimide respectively with 
p-cyanobenzyloxyphtalimide, 2-hydroxy-4-nitroben-
zyloxyphtalimide, and p-carboxybenzyl oxyphtalimide. 10 
O-(p-Chlorobenzyl)-N-(3-hydroxy-2-pyridinemethy-
lene) hydroxylamine. 0-(4-Chlorobenzyl) hydroxylam-
ine hydrochloride (9.75 g, 50 mmol) was neutralized 
with NaOH (2.0 g, 50 mmol dissolved in 20 mL H20). 
Ethanol (20 mL) was added to solubilize the resulting 15 
hydroxylamine. 3-Hydroxy-2-pyridinealdehyde (6.2 g, 
24 
ybenzyl)-N-(3-hydroxy-2-pyridinemethylene) hydroxy-
lamine. O-(p-Chlorobenzyl)-N-(5-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride, O-(p-
cyanobenzyl)-N-(5-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride, 0-(2-
hydroxy-4-nitro benzyl)-N-(5-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride, and 0-(p-
carboxy benzyl)-N-(5-hydroxy-l-methyl-2-
pyridinemethylene) hydroxylamine chloride can be 
made by the same procedure replacing 3-hydroxy-2-
pyridine aldehyde with 2-formyl-5-hydroxy pyridine. 
EXAMPLE 5 
Preparation of 
O-(p-Methoxybenzyl)-N-(3-hydrox y-1-methyl-2-
pyridinemethylene) hydroxylamine chloride (le) 
O-(p-Methoxybenzyl)-N-(3-hydroxy-2-
pyridinemethylene) hydroxylamine. 0-(p-methoxyben-
zyl) hydroxylamine (5.55 g, 29 mmol; Grochowski et al, 
1976 and Schumann et al, 1964, vide supra) was added 
to a solution ofNaOH (1.2 g, 29 mmol) in 15 mL H20. 
3-Hydroxy-2-pyridine carbaldehyde (3.6 g, 29 mmol) 
was then added, followed by 15 mL of 95% EtOH and 
50 mmol) dissolved in H20 (150 mL) was added and the 
mixture heated on a steam bath for 30 min. The solution 
was cooled to room temperature. The product crystal-
lized out as long pale yellow needles. The mixture was 20 
filtered to isolate the pure product (12.5 g, 96%), m.p. 
89°-90° C. IH NMR(CDC)J) o: 9.67 (s, lH); 8.33 (s, 
lH); 7.33-7.13 (m, 7H); 5.17 (s, 2H). Anal. Calcd. for 
C13H11N202CI: C, 59.43; H, 4.23; N, 10.67; Cl, 13.49. 
Found: C, 59.43; H, 4.26; N, 10.64; Cl, 13.56. 25 10 mL of acetone. The reaction mixture was stirred at 
room temperature for 4 h and was then poured over 400 
mL of crushed ice. A beige solid comes out of solution 
upon scratching the sides of the beaker. It was filtered, 
washed with water and dried to yield 7.03 g (93%) of 
O-(p-Chlorobenzyl)-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine iodide. A solution 
of O-(p-chlorobenzyl)-N-(3-hydroxy-2-pyridinemethy-
lene) hydroxylamine (1.0 g, 3.8 mmol) in EtOH (45 mL) 
was placed in a glass pressure tube. Methyl iodide (I 30 
mL, 16.0 mmol) was then added, and the tube was 
sealed tightly. The tube was heated at 69° C. in an oil 
bath for 20 h. The solution was concentrated in vacuo. 
The oily residue was triturated with acetone to give the 
crude product as a yellow solid (1.46 g, 95'7<- ). Recrys- 35 
tallization from acetone gave the pure product as a 
shiny yellow solid (0.8 g, 52%), m.p. 164°-166' C. IH 
NMR (CDCl3/DMSO-d6) o: 8.83-8.67 (m, 2H); 
8.13-7.67 (m, 2H); 7.33 (s, 4H); 5.00 (s, 2H); 4.43 (s, 3H). 
Anal. Calcd. for C14H14N202Cll: C, 41.55; H, 3.49; N, 40 
6.92; Cl, 8.76; I, 31.36. Found: C, 41.62; H, 3.53; N, 6.92; 
Cl, 8.71; I, 31.28. 
O-(p-Chlorobenzyl)-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride. To a solu-
tion of the corresponding pyridinium iodide (1.0 g, 2.47 45 
mmol) in CH3CN/H20 (1:1, 15 mL) was added freshly 
made AgCI (from 0.54 g AgN03 and cone. HCI). The 
mixture was allowed to stir at room temperature for 1.5 
h. It was then filtered through a bed of Celite. The 
solvent was removed in vacuo. Trituration of the resi- 50 
due with acetone gave the pure pyridinium chloride 
(0.72 g) in 93% yield, m.p. 175° C. (dee). IH NMR 
(CDCl3/DMSO-d6) o: 8.67 (m, lH); 8.37 (m, lH); 
8.00-7.67 (m, lH); 7.37 (s, 4H); 5.3 (s, 2H); 4.33 (s, 3H). 
Anal. Calcd. for C14H14N202Cli: C, 53.68; H, 4.51; N, 55 
8.95; Cl, 22.64. Found: C, 53.76; H, 4.56; N, 8.92; Cl, 
22.57. 
O-(p-Cyanobenzyl)-N-(3-hydroxy-1-methy 1-2-
pyridinemethylene) hydroxylamine chloride, 0-(2-
hydroxy-4-nitrobenzyl)-N-(3-hydroxy-1-methyl-2- 60 
pyridinemethylene) hydroxylamine chloride, and O-(p-
carboxybenzyl)-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride can be 
made by the same procedure replacing 0-(p-chloroben-
zyl) hydroxylamine respectively with 0-(p-cyanoben- 65 
zyl)-N-(3-hydroxy-2-pyridinemethylene) hydroxylam-
ine, 0-(2-hydroxy-4-nitrobenzyl)-N-(3-hydroxy-2-
pyridinemethylene) hydroxylamine, and 0-(p-carbox-
product; m.p. 79°-81° C. IH NMR (CDCl3) o: 9.85 (s, 
lH); 8.38 (s, lH); 8.19 (d of d, lH); 7.36 (d of d, 2H); 7.28 
(d ofd, lH); 7.18 (d ofd, lH); 6.93 (d ofd, 2H); 5.15 (s, 
2H); 3.82 (s, 3H). 
O-(p-Methoxybenzyl)-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride. Methyl 
iodide (7.2 mL, 0.12 mol) was added to a solution of 
O-(p-methoxy)benzyl-N-(3-hydroxy-2-pyridinemethy-
lene) hydroxylamine (3.72 g, 14 mmol) in 60 mL of 
acetonitrile. The resulting mixture was divided into 
three pressure glass vessels and heated at 70° C. for 3 
days. The solvent was removed in vacuo and the resi-
due was triturated with ether/acetone (3:1); after dry-
ing, the methiodide weighed 4.88 g (85% ). It was dis-
solved in 500 mL H20 and 300 mL of acetonitrile and 
freshly made AgCI (2 eq.) was then added. The suspen-
sion was stirred at room temperature for 1.5 h and then 
filtered through Celite. The filtrate was concentrated to 
dryness in vacuo and the residue was triturated with 
acetone/ether (1:1). The yellow solid was filtered, 
washed first with acetone/ether (1:1), then with ether 
and dried to yield 3.57 g (97%) of pure product, m.p. 
183°-184° C. (dee.). IH NMR (d6DMSO) o: 8.57 (d, lH, 
J = 6.1 Hz); 8.50 (s, lH); 8.19 (d, lH, J = 8.2 Hz); 7.88 (d 
of d, IH, J = 6.1 Hz, J = 8.2 Hz); 7.38 (d, 2H, J = 8:7 Hz); 
6.95 (d, 2H, J =8.7 Hz); 5.25 (s, 2H); 4.26 (s, 3H); 3.75 (s, 
3H). Anal. Calcd. for C1sH11CIN203 x 0.55H20: C, 
6.53; H, 5.73; N, 8.79; Cl, 11.13. Found: C, 56.53; H, 
5.72; N, 8.79; Cl, 11.18. 
O-(p-Dimethylaminocarbonyloxybenzy l)-N-( 3-
hydroxy-1-methyl-2-pyridinemethylene) hydroxylam-
ine chloride, 0-(p-propylaminocarbonylbenzyl)-N-( 3-. 
hydroxy-1-methyl-2-pyridinemethylene) hydroxy )am-
ine chloride, and 0-(p-ethoxycarbonyl benzyl)-N-(3-
hydroxy-l-methyl-2-pyridinemethylene) hydroxylam-
ine chloride can be made by the same procedure replac-
ing 0-(p-methoxybenzyl) hydroxylamine in the above 
example respectively with 0-(p-dimethylaminocar-
bonyloxy benzyl) hydroxylamine, 0-(p-
25 
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C17H20CIN303 x 0.45 H20: C, 57.04; H, 5.89; N, 11.74; 
Cl, 9.91. Found: C, 56.99; H, 5.95; N, 11.69; Cl, 9.91. 
0-Benzyl-N-[3-(N' ,N' -diethylcarbamoyl)hydroxy-1-
methyl-2-pyridinemethylene ]hydroxylamine chloride 
propylaminocarbonyl benzyl) hydroxylamine, and 0-
(p-ethoxycarbonyl benzyl) hydroxylamine. 0-(p-
Methoxybenzyl)-N-( 5-hydroxy- l-methyl-2-
pyridinemethylene) hydroxylamine chloride, 0-(p-
dimethylaminocarbonyloxy benzyl)-N-(5-hydroxy-1-
methyl-2-pyridinemethylene) hydroxylamine chloride, 
0-(p-propylaminocarbonyl benzyl)-N-(5-hydroxy-1-
methyl-2-pyridinemethylene) hydroxylamine chloride, 
and 0-(p-ethoxycarbonyl benzyl)-N-(5-hydroxy-l-
methyl-2-pyridinemethylene) hydroxylamine chloride 
can be made by the same procedure replacing 3-
hydroxy-2-pyridine aldehyde in the above example with 
2-formyl-5-hydroxy pyridine. 
5 and O-benzyl-N-[3-(N',N'-difluoroethylcarbamoyl)hy-
droxy-1-methy 1-2-pyridinemethy Jene ]hydroxy I amine 
chloride can be made by the same procedure replacing 
N,N-dimethylcarbamoyl chloride respectively with 
N,N-diethylcarbamoyl chloride and N,N-difluoroethyl-
10 'Carbamoyl chloride. 0-Benzyl-N-[5-(N',N'-dimethyl-
carbamoyl) hydroxy-1-methyl-2-pyridinemethylene ]· 
hydroxylamine chloride, 0-benzyl-N-[5-(N',N' -diethyl-
carbamoy l)hydroxy-1-methy 1-2-pyridinemethy Jene ]h Y· 
droxylamine chloride and O-benzyl-N-[5-(N',N'-
EXAMPLE 6 
Preparation of 
0-Benzyl-N-[3-(N' ,N' -dimethylcarbamoyl)hydroxy-1-
methyl-2-pyridinemethylene]hydroxylamine chloride 
(2a) 
15 difluoroethylcarbamoyl)hydroxy-1-methyl-2-
pyridinemethylene ]hydroxylamine chloride can be 
made by the same procedure replacing 3-hydroxy-2-
pyridine aldehyde with 2-formyl-5-hydroxy pyridine. 
0-[2-( 1-Methyl-1-piperidinium)ethyl]-N-[3-(N' ,N' -
0-Benzyl-N-[3-(N' ,N'-dime thy lcarbamoyl)hydroxy-
2-pyridinemethy lene ]hydroxy lamine. Dimethylcarba-
myl chloride (7 mL, 76 mmol) was added to a solution 
20 dimethylcarbamoyl)hydroxy-1-methyl-2-pyridineme-
thylene]hydroxylamine dichloride, and 0-[2-(trime-
thylammonium )ethy J ]-N-[3-(N' ,N' -dimethylcar-
bamoyl)hydroxy-1-methyl-2-pyridinemethylene ]hy-
of 2.59 g (11 mmol) of O-benzyl-N-(3-hydroxy-2-
pyridinemethylene]hydroxylamine (prepared as re- 25 
ported on previous page) in 20 mL of pyridine. The 
resulting mixture was stirred at 65' C. for 12 h and 
poured over 400 mL of ice water. The aqueous solution 
was extracted with ether (6 X 50 mL); the ether layer 
was dried (Na2S04), filtered and concentrated to dry- 30 
ness to a yellow oil which was coevaporated with H20 
and with acetone to remove the remaining pyridine. 
The residue was dissolved in IO mL acetone, and water 
was added with cooling and stirring until no more pre-
cipitate came out of solution. The white solid was fil- 35 
tered, washed with water and dried to yield 3.02 g 
(89%) of product; m.p. 65'-66' C. lH NMR (CDCl3) o: 
8.54 (d of d, lH, J =4Hz, J = lHz); 8.38 (s, lH); 7 .54 (d 
of d, lH, J = 8.3 Hz, J = 1.5 Hz); 7.30-7.43 (m, 6H); 5.30 40 (s, 2H); 3.06 (s, 3H); 2.97 (s, 3H). 
0-Benzy 1-N-[ 3-(N' ,N' -dimeth y Icarbamoy l)hydroxy-
1-methy l-2-pyridinemethy lene ]hydroxy lamine iodide. 
A solution of 2.95 g (9.9 mmol) of 0-benzyl-N-[3-
(N' ,N' -dimethylcarbamoyl)hydroxy-2-pyridinemethy- 45 Jene] hydroxylamine and 2.8 mL (44 mmol) of methyl 
iodide in 20 mL of acetonitrile was heated at 65' C. in a 
glass pressure bottle for 2 days. The reaction mixture 
was concentrated to dryness to a dark orange oil which 
was triturated with cold acetone to yield a bright ye!- 50 
low precipitate that was washed with acetone and 
ether. After drying the product weighed 4.02 g (92%). 
0-Benzy J. N-[3-(N' ,N' -dimethylcarbamoyl)hydroxy-
1-methyl-2-pyridinemethylene ]hydroxylamine chlo-
ride. The methiodide obtained in the previous step (4.02 55 
g, 9 mmol) was dissolved in 25 mL H20 and 20 mL 
acetonitrile. Freshly prepared AgCI (2.61 g, 18 mmol) 
was added to this solution and the resulting suspension 
was stirred at room temperature for 1 h. The reaction 
mixture was filtered and the filtrate was concentrated to 60 
dryness to a white solid that was triturated with warm 
(40' C.) acetone for 20 min and filtered. The white solid 
was washed with acetone and ether to yield 3.2 g (quan-
titative) of the pure chloride, m.p. 150'-152' C. (dee.); 
IH NMR (DMSO-d6) o: 9.09 (d, J =5.5 Hz, lH); 8.74 (s, 65 
lH); 8.59 (d, J=8.4 Hz, lH); 8.19 (d of d, 1=8.4 Hz, 
J = 5.5 Hz, lH); 7.42 (m, SH); 5.33 (s, 2H); 4.39 (s, 3H); 
2.98 (s, 3H); 2.92 (s, 3H). Anal. Calcd. for 
droxy !amine dichloride can be made by the same proce-
dure replacing 0-benzylhydroxylamine in the above 
example with 0-[2-( 1-piperidine )ethyl]hydroxylamine 
and 0-[2-(dimethylamino)ethyl]hydroxylamine. 
EXAMPLE 7 
Preparation of 
O-(Diphenylmethyl)-N-[3-(N',N'-dimethylcarbamoyl)-
hydroxy-1-methyl-2-pyridinemeth y Jene ]hydroxy !amine 
chloride (2b) 
O-(Diphenylmethyl)-N-(3-hydroxy-2-pyridineme-
thylene]hydroxylamine. 0-Diphenylmethyl hydroxy-
lamine (3.4 g, 14.4 mmol; Grochowski et al, 1976 and 
Schumann et al, 1964, vide supra) was added to a solu-
tion of NaOH (0.58 g, 14.4 mmol) in 7 mL of water. 
3-Hydroxy-2-pyridine carbaldehyde (1.8 g, 14.4 mmol) 
was added to this solution and the resulting mixture was 
stirred at room temperature for 4 h. The white solid in 
the reaction mixture was filtered, washed with H20/E-
tOH (1:1) and dried to yield 3.17 (72%) of product, m.p. 
82'-83' C. lH NMR (CDCl3) o: 9.60 (s, lH); 8.51 (s, 
lH); 8.2 (d of d, lH); 7.30-7.43 (m, JOH); 7.23 (d of d, 
lH); 7.16 (d of d, lH); 6.29 (s, lH). 
0-(Diphenylmethyl)-N-[3-(N' ,N' -dimethy Jcar-
bamoy I )hydroxy-2-pyridinemeth ylene ]hydroxy lamine. 
Dimethylcarbamyl chloride (9 mL, 98 mmol) was 
added to a solution of O-(diphenylmethyl)-N-(3-
hydroxy-2-pyridinemethylene]hydroxylamine (3.0 g, 
9.9 mmol) in 30 mL of pyridine. The resulting mixture 
was stirred at room temperature for 14 h and poured 
over 400 mL of crushed ice. A white solid precipitates 
upon scratching the sides of the beaker. It was filtered, 
washed thoroughly with water and dried to yield 3.47 g 
(94%) of product, m.p. 89'-90' C. lH NMR (d6-
DMSO) o: 8.49 (d of d, lH); 8.37 (s, lH); 7.64 (d of d, 
lH); 7.47 (d of d, lH); 7.42-7.28 (m, JOH); 6.29 (s, lH); 
2.81 (s, 3H); 2. 74 (s, 3H). 
0-(Diphenylmethyl)-N-[3-(N',N'-dimethylcar-
bamoyl)h ydroxy-1-methyl-2-pyridinemethylene ]hy-
droxy lamine chloride. Methyl iodide (2.8 mL, 46 mmol) 
was added to a solution of 0-(diphenylmethyl)-N-[3-
(N' ,N'-dime thy lcarbamoy !)hydroxy-2-pyridinemeth y-
lene] hydroxylamine (3.44 g, 9.2 mmol) in 40 mL of 
acetonitrile. The resulting mixture was divided into two 
27 
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pressure glass vessels and heated at 70° C. for 3 days. ture of H20/acetonitrile (200 mL) and then freshly 
The solvent was removed in vacuo and the residue (4.92 made AgCI (21 mmol, washed well with water) was 
g) was dissolved in a mixture of acetonitrile/water (200 added. The resulting suspension was stirred at room 
mL:200 mL). Freshly made AgCI <2 eq, washed well temperature for 2 h and filtered through Celite. The 
with H10) was added to this solution and the resulting 5 
suspension was stirred at room temperature for 2 h. It filtrate was concentrated to dryness in vacuo and the 
was filtered through Celite and the filtrate was concen- residue was triturated with 1:1 acetone/ether. The 
trated to dryness in vacuo to a residue that was tritu- white solid that resulted was filtered, washed with ether 
rated with ether. The white solid was collected by fil- and dried to yield 3.72 g (84.4%) of pure chloride, m.p. 
tration and dried to yield 3.84 g (98%) of pure product, 10 145°-6° C. (dee.). Anal. Calcd. for C1sH22CIN304X0.5 
m.p. 153°-154° C. (dee.). 1H NMR (d6-DMSO) o: 9.06 H20: C, 55.59; H, 5.96; N, 10.81; Cl, 9.12. Found: C, 
(d, lH, J =f 6.0l~z)} 8.!7o (ii lH} 8.55 (d, lH, 1;= ~·io H(z); 55.59; H, 6.03; N, 10. 76; Cl, 9.17. 
8.18 (d 0 d, ' = · z, = 8·4 Hz); 7· - · m, O-(p-Methoxybenzyl)-N-[3-(N', N'-dimethylcar-lOH); 6.44 (s, lH); 4.35 (s, 3H); 2.8 (s, 3H); 2.79 (s, 3H). 
Anal. Calcd. for c23H24CJN3o3 x 1.19 tt2o: c, 61.76; 15 bamoyl)hydroxy-1-ethyl-2-pyridinemethylene]hydrox-
H, 5.94; N, 9.39; Cl, 7.93. Found: C, 61.76; H, 6.02; N, ylamine chloride, O-(p-methoxybenzyl)-N-[3-(N',N'-
9.41; Cl, 7.97. dimethylcarbamoyl)hydroxy-1-benzyl-2-pyridineme-
0-(Diphenylmethyl)-N-[3-(N' -isopropylcarbamoyl)- thylene]hydroxylamine bromide, O-(p-methoxybenzyl)-
hydroxy-l-methyl-2-pyridinemethylene ]hydroxylamine N-[3-(N' ,N' -dimethylcarbamoyl)hydroxy-1-(1-naphtyl-
chloride and O-(diphenylmethyl)-N-[3:[~'-(2-fluoroe- 20 methyl)-2-pyridinemethylene]hydroxylamine chloride, 
thyl)carbamoyl]hydroxy-l-methyl-2-pyndmeme- 0 ( th b I) N [3 (N' N' d" th J thylene]hydroxylamine chloride can be made by the - p-me oxy enzy - - - ' - ime Y car-
same procedure replacing N,N-dimethylcarbamyl chlo- ba~o~l)hydroxy-1-(2-methyl-1-~aphtylmet~yl)-2-
ride respectively with isopropyl isocyanate and 2- pyndmemethylene]hydroxylamme chlonde, 0-(p-
fluoroethyl isocyanate. 0-(Diphenylmethyl)-N-[5-(N' - 25 methoxybenzyl)-N-[3-(N' ,N' -dimethylcarbamoyl)hy-
isopropylcarbamoy l)hydroxy- l-methyl-2-pyridineme- droxy-1-diphenylmethyl-2-pyridinemethylene ]hydrox-
thylene ]hydroxy lamine chloride and 0-(diphenylme- ylamine chloride, 0-(p-methoxybenzyl)-N-[3-(N',N'-
thyl )-N-[ 5-[N_'-~2-fluoroethyl)carbamoyl]~ydroxy-1- . dimethylcarbamoyl)hydroxy-1-(2-hydroxy-4-nitroben-
methyl-2-pyndmemeth y lene ]hydroxy lamme c~londe zyl)-2-pyridinemethylene]hydroxylamine chloride, 0-
can be made by the same procedure replacmg 3- 30 , , . hydroxy-2-pyridine aldehyde with 2-formyl-5-hydroxy (p-methoxybenzyl)-N-[3-(N ,N -d1methylcarbamoyl)-
pyridine. hydroxy-1-(p-carboxybenzyl)-2-pyridinemethylene ]hy-
EXAMPLE 8 
droxylamine chloride, and 0-(p-methoxybenzyl)-N-[3-
(N' ,N' -dimethylcarbamoyl)hydroxy- l-(p-cyanobenzyl)-
Preparation of 
0-(p-Methoxybenzyl )-N-[3-(N' ,N' -dimethy lcar-
bamoyl )hydroxy-1-methy l-2-pyridinemethylene ]hy-
droxylamine chloride (2c) 
35 2-pyridinemethylene]hydroxylamine chloride can be 
made by the same procedure replacing methyl iodide in 
the above example respectively with ethyl iodide, ben-
zyl bromide, 1-chloromethyl naphtalene, 1-chlorometh-
yl-2-methyl naphtalene, chlorodiphenylmethane, 2-
chloromethyl-4-nitrophenol, 4-chloromethyl benzoic 
acid, and 4-cyano benzyl chloride. 0-(p-Methoxyben-
zyl)-N-[5-(N' ,N' -dimethylcarbamoyl)hydroxy-1-meth-
yl-2-pyridinemethylene]hydroxylamine chloride, 0-(p-
methoxybenzyl)-N-[ 5-(N' ,N' -dimethylcarbamoy l)hy-
droxy-1-ethy 1-2-pyridinemethylene ]hydroxy !amine 
chloride, 0-(p-methoxybenzyl)-N-[5-(N' ,N'-dimethyl-
carbamoyl)hydroxy-1-benzyl-2-pyridinemethylene ]hy-
droxylamine bromide, 0-(p-methoxybenzyl)-N-[5-
(N' ,N' -dimethylcarbamoyl)hydroxy-1-( 1-naphtylme-
thyl)-2-pyridinemethylene ]hydroxylamine chloride, 
0-(p-methoxybenzy 1)-N-[ 5-(N' ,N' -dimethylcar-
bamoyl)hydroxy-1-(2-methyl-1-naphtylmethyl)-2-
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar-
bamoyl)hydroxy-2-pyridine methylene]hydroxylamine. 40 
Dimethylcarbamyl chloride (10 mL, 0.11 mo!) was 
added to a solution of O-(p-methoxybenzyl)-N-(3-
hydroxy-2-pyridinemethylene) hydroxylamine (3.3 g, 
12.8 mmol) in 30 mL of pyridine. The resulting mixture 
was stirred at room temperature for 14 h and then 45 
poured over 400 mL of crushed ice. Since it was not 
possible to induce precipitation of the product, the 
aqueous mixture was extracted with ether (4X 100 mL) 
and the organic extract was concentrated to dryness in 
vacuo. The oily residue was coevaporated with water 50 
to remove traces of pyridine and then with acetone. The 
300 MHz 'H NMR of the resulting yellow oil shows no 
pyridine or water and was used in the next step without 
further purification. 
55 pyridinemethylene]hydroxylamine chloride, 0-(p-
methoxybenzyl)-N-[5-(N',N'-dimethylcarbamoyl)hy-
droxy- l-diphenylmethyl-2-pyridinemethylene ]hydrox-
ylamine chloride, 0-(p-methoxybenzyl)-N-[5-(N',N' -
0-(p-Methoxybenzy 1)-N-[3-(N' ,N' -dimethylcar-
bamoyl)hydroxy-1-methyl-2-pyridinemethylene ]hy-
droxy !amine chloride. Methyl iodide (2.9 mL, 46.4 
mmol) was added to each of two pressure glass tubes 
containing a solution of 0-(p-methoxybenzyl)-N-[3-
(N' ,N' -dimethylcarbamoyl)hydroxy-2-pyridineme- 60 
thylene]hydroxylamine (3.82 g, 11.6 mmol, divided into 
two) in 40 mL of acetonitrile. The sealed reaction ves-
sels were heated at 70° C. for 3 days and then the sol.-
vent was removed in vacuo. The resulting oil crystal-
lizes upon standing at o· -5° c. for 14 h in a 2: 1 mixture 65 
of acetone/ether (75 mL). The yellow solid was fil-
tered, washed with ether and dried to yield 4.94 g 
(90%) of crude methiodide. It was dissolved in 1: I mix-
dimethylcarbamoyl)hydroxy-1-(2-hydroxy-4-nitroben-
zyl)-2-pyridinemethylene ]hydroxylamine chloride, 0-
(p-methoxybenzyl)-N-[ 5-(N' ,N' -dimethylcarbamoyl)-
hydroxy- l-(p-carboxybenzyl)-2-pyridinemethylene ]hy-
droxylamine chloride, 0-(p-methoxybenzyl)-N-[5-
(N' ,N' -dimethylcarbamoyl)hydroxy-1-(p-cyanobenzyl)-
2-pyridinemethylene ]hydroxylamine chloride can be 
made by the same procedure replacing 3-hydroxy-2-
pyridine aldehyde with 2-formyl-5-hydroxy pyridine. 
5,180,831 
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EXAMPLE 9 
Preparation of 
30 
of acetonitrile. The resulting mixture was put into a 
glass pressure vessel and heated at 80' C. for 3 days. 
The solvent was removed in vacuo and the residue was 
dissolved in a minimum quantity of acetone, triturated N-[5-(N' ,N' -Dimethylcarbamoyl)hydroxy-1-methyl-2-
pyridine methylene]hydroxylamine chloride (2d) 5 with ether and placed in the freezer overnight. A dark 
yellow solid resulted and was filtered under vacuum 
and washed with 1:1 ether/acetone to yi~ld 3.25 g of the 
iodide salt. Freshly made AgCl (2 eq, washed well with 
2-Formyl-5-hydroxypyridine. To a stirred solution of 
21.8 g of 5-hydroxy-2-picoline (0.2 mo!) in 200 mL of 
glacial acetic acid was added 18 mL of 30% hydrogen 
peroxide (0.159 mo!) in one portion. The mixture was 
heated in an oil bath at 80° -85' c. with stirring for 3 h. 10 
Then another 18 mL of hydrogen peroxide was added 
and the mixture was stirred for 3 h at the same tempera-
ture. Excess solvent was removed in vacuo followed by 
the addition of acetone, which caused the pyridine N-
oxide to crystallize. Without further purification, 200 15 
mL of acetic anhydride was added to the solid and the 
mixture was heated at 120' C. with stirring in an oil bath 
for 2 h. After cooling to room temperature, excess 
acetic anhydride was removed by high vacuum distilla-
tion. The oily material was again oxidized with 30% 20 
hydrogen peroxide twice and rearranged with acetic 
anhydride following the same procedure and amounts 
depicted above. The black oily material obtained was 
hydrolyzed with 200 mL of IN HCl (0.2 mo!) at room 
temperature for 3 weeks (hydrolysis at higher tempera- 25 
ture may be harmful to the pyridine nucleus). The mix-
ture was neutralized with anhydrous sodium carbonate, 
indicated by litmus paper and then extracted three times 
with 300 mL of diethylether. The combined ether ex-
tracts were dried (MgS04), filtered and evaporated to 30 
leave a solid material in a small amount of oil. The pure 
product (7.8 g, 32%) was obtained by filtering the solid, 
followed by washing it with a small amount of ether. It 
is yellow in color and shows a sharp melting point at 
186'-187' C. IH NMR (d6-DMSO) o: 11.10 (br. s, lH, 35 
OH); 9.87 (s, lH, CHO); 8.35 (d, J =2 Hz, lH); 7.58 (d, 
1=9 Hz. lH); 7.35 (d ofd, J=2 Hz, 9 Hz, lH). 
N-(5-Hydroxy-2-pyridinemethylene) hydroxylamine. 
To 200 mL of 2.5% (w/w) sodium hydroxide solution 
was dissolved 5.5 g of 5-hydroxy-2-formylpyridine (45 40 
mmol). Subsequently 12.5 g ofhydroxylamine HCl (180 
mmol) was added to the solution in one portion. The 
solution turned cloudy after being stirred for 10 min-
utes. After stirring at room temperature for 3 h, the 
precipitate was filtered under vacuum and dried in the 45 
air for several days to yield 4.8 g of N-(5-hydroxy-2-
pyridinemethylene) hydroxylamine (78%). The solid is 
of white and decomposes at 195' C. IH NMR (d6-
DMSO) o: 11.27 (br. s, lH); 10.83 (br. s, lH); 8.18 (d, 
J=2 Hz, lH); 8.05 (s, lH, CH=N); 7.72 (d, J=9 Hz, 50 
lH); 7.25 (d of d, J =2 Hz, 9 Hz, lH). 
N-[5-(N' ,N' -Dimethylcarbamoyl)hydroxy-2-pyridine 
methylene]hydroxylamine. Dimethylcarbamoyl chlo-
ride (5.2 mL, 57 mmol) was added to a solution ofN-(5-
hydroxy-2-pyridinemethylene) hydroxylamine (6.53 g, 55 
47 mmol) in 40 mL of pyridine. It was stirred at room 
temperature overnight and then the solvent was re-
moved in vacuo, leaving a light green paste. The paste 
was dissolved in a minimum quantity of acetone and 
then triturated with ethyl acetate and placed in the 60 
freezer overnight. Glassy needles formed and were 
filtered and washed with ethyl acetate to yield 3.0 g of 
pure product (30%), m.p. 134°-135' C. 
N-[5-(N' ,N' -Dimethylcarbamoyl)hydroxy-1-methyl-
2-pyridinemethylene]hydroxylamine chloride. Methyl 65 
iodide (5.3 mL, 85 mmol) was added to a solution of 
N-[ 5-(N' ,N' -dimethy lcarbamoyl)hydroxy-2-pyridine 
methylene]hydroxylamine (2.8 g, 13.4 mmol) in 25 mL 
water) was added to the iodide salt in acetonitrile/water 
(60 mL/100 mL) and stirred for several hours. After 
filtration, the residue was crystallized from aceto-
ne/ether and dried in the air for several days to yield 2.5 
g of the chloride salt (monohydrate, 72% yield); m.p. 
159'-160° C. IH NMR (d6-DMSO) o: 9.18 (s, lH); 8.65 
(s, lH); 8.40 (d of d, 2H, J = 2 Hz, 9 Hz); 4.36 (s, 3H); 3.3 
(s, HiO); 3.1 (s, 3H); 2.95 (s, 3H). Anal. Calcd. for 
C10H14N303Cl.H20: C, 43.25; H, 5.81; N, 15.13; Cl, 
12.76. Found: C, 43.42; H, 5.81; N, 15.09; Cl, 12.87. 
N-[3-(N' ,N' -Dimethylcarbamoyl)hydroxy-1-methyl-
2-pyridinemethylene ]hydroxylamine chloride can be 
made by the same procedure replacing 2-formyl-5-
hydroxypyridine with 3-hydroxy-2-pyridine carbalde-
hyde. 
EXAMPLE 10 
Preparation of 
2-[[ (Aminocarbonyl)hydrazono ]methy l]-3-hydroxy- l-
methy l pyridinium chloride (3a) 
2-[[(Aminocarbonyl)hydrazono]methyl]-3-hydroxy 
pyridine. Sodium acetate (2.21 g, 16 mmol) was dis-
solved in 25 mL of water and then semicarbazide hy-
drochloride was added (1.81 g, 16 mmol), followed by 
3-hydroxy-2-pyridine aldehyde (2.0 g, 16 mmol). The 
resulting mixture was stirred at room temperature for 2 
h. The solid in the reaction mixture was then filtered, 
washed with water and dried to yield 2.71 g (93%) of 
the semicarbazone. It was used in the next step without 
further purification; m.p.: 215°-217° C. (dee.). 
2-[[(Aminocarbonyl)hydrazono]methyl]-3-hydroxyl-
lmethyl pyridinium iodide. A glass pressure tube con-
taining a stirring bar was charged with 20 grams (11.1 
mmoles) of 2-[[(aminocarbonyl)hydrazono]methyl]-3-
hydroxy pyridine, 2.5 g of barium carbonate, 7.0 g (49.3 
mmol) of methyl iodide and 30 mL of DMF. The reac-
tion mixture was stirred for two days at 65' C. in an oil 
bath. After that time the solvent was removed in vacuo, 
the residue shaken with 50 mL of warm water and 
filtered. The filtrate was then treated with an aqueous 
solution of HiS04 in amount needed for the precipita-
tion of Ba2+ present in the solution. After collecting 
BaS04, the filtrate was concentrated and crystallized 
from a mixture of water and ethanol to afford 2.1 g 
(58.3%) of the methiodide salt, m.p. 180' -182' C. 
2-[[(Aminocarbonyl)hydrazono]methyl]-3-hydroxy-
l-methyl pyridinium chloride. The preceeding iodide, 
6.0 grams (18.6 mmol) was dissolved in 150 mL of water 
and stirred with silver chloride precipitated from a 
solution of 6.0 g (35.3 mmol) of silver nitrate with ex-
cess of aqueous HCI. After 40 min the reaction mixture, 
was filtered and the precipitate washed with a total of 
100 mL of warm water. Pale yellow crystals of product 
melting at 230' -232' C. (dee.) were obtained from the 
combined filtrate by both rotoevaporation and precipi-
tation with acetone. Yield 4.12 grams (95.3%). IH NMR 
(D20, TSP) o: 8.45 (s, lH), 8.36 (d, lH, J = 5.8 Hz), 8.03 
(d, lH, J = 8.3 Hz), 7.80 (d of d, lH), 4.42 (s, Me). Anal. 
31 
5,180,831 
Calcd for CsH11N402Cl: C, 41.66; H, 4.81; N, 24.28; Cl, 
15.37. Found C, 41.59, H, 4.85; N, 24.28; Cl, 15.44. 
32 
was dried to yield 5.13 g (89%) of methiodide. It was 
dissolved in a mixture of water/acetonitrile (500 mL: 
300 mL) and then freshly made AgCJ (2 eq) was added. 
The suspension was stirred at room temperature for 2 h 
2-[[(Aminothiocarbonyl)hydrazono]methyl]-3-
hydroxy-l-methyl pyridinium chloride, 2-
hydrazonomethyl-3-hydroxy-l-methyl pyridinium 
chloride, 1-methyl-2-(3-hydroxy- l-methyl-2-
pyridinemethylene) hydrazine chloride, l-methyl-1-
pheny 1-2-( 3-h ydroxy- l-methyl-2-pyridinemethylene) 
hydrazine chloride, l, l-diphenyl-2-(3-hydroxy- l-meth-
yl-2-pyridinemethylene) hydrazine chloride, l-(2,4-dini-
trophenyl)-2-(3-hydroxy-l-methy 1-2-pyridinemethy-
lene) hydrazine chloride, and l-(2-naphtyl)-2-(3-
hydroxy-l-methyl-2-pyridinemethylene) hydrazine 
chloride can be made by the same procedure replacing 
semicarbazide in the above example respectively with 
thiosemicarbazide, hydrazine, methylhydrazine, 1-
methyl-1-phenylhydrazine, I, 1-diphenylhydrazine, 2,4-
dinitrophenylhydrazine, and 2-naphtylhydrazine. 2-
5 and then filtered through Celite. The filtrate was con-
centrated to dryness in vacuo and the residu". was tritu-
rated with acetone. The yellow solid was filtered, 
washed with acetone and dried to yield 3.67 g (93%) of 
the pure chloride; m.p. 220°-221° C. (dee.). It can be 
10 recrystallized from EtOH. IH NMR (d6·DMSO) 8: 
11. 74 (br.s., IH); 9.27 (s, IH); 8.58 (d, IH, 1=5. 7 Hz); 
8.39 (s, IH); 8.17 (d, IH, 1=8.2 Hz); 7.85 (d of d, IH, 
1=5.7 Hz, 1=8.2 Hz); 7.57 (d, 2H, 1=7.6 Hz); 7.31 (t, 
2H, 1=7.6 Hz); 7.04 (t, lH, 1=7.6 Hz); 4.48 (s, 3H). 
15 Anal. Calcd. for C14H1sCIN402X0.95 HiO: C, 51.90: 
H, 5.26; N, 17.29; Cl, 10.94. Found: C, 51.90; H, 5.22; N, 
17.36; Cl, 10.89. 
3-Hydroxy-1-methyl-2-[[ (N-pheny Jaminothiocar-
bonyl)hydrazono ]methyl]pyridinium chloride, 2-[[ (Aminocarbony l)hydrazono ]methy J]-5-hydroxy- I-
methyl pyridinium chloride, 2-[[(aminothiocarbonyl)-
hydrazono ]methyl]-5-hydroxy- l-methyl pyridinium 
chloride, 2-hydrazonomethyl-5-hydroxy-1-methyl pyri-
dinium chloride, l-methyl-2-(5-hydroxy-J-methyl-2-
pyridinemethylene) hydrazine chloride, J-methyl-1-
20 [[(N,N-diphenylaminocarbonyl)hydrazono]methyl]-3-
hydroxy-l-methyl pyridinium chloride, 2-[[(N,N-dime-
thylaminothiocarbonyl)hydrazono ]methyl]3-hydroxy-
1-methyl pyridinium chloride, 2-[[(N-ethylaminothi-
phenyl-2-(5-hydroxy-l-methyl-2-pyridinemethylene) 25 
hydrazine chloride, 1, J-diphenyl-2-(5-hydroxy-1-meth-
yl-2-pyridinemethylene) hydrazine chloride, 1-(2,4-dini-
tropheny 1)-2-( 5-hydroxy-1-methy 1-2-pyridinemeth y-
lene) hydrazine chloride, and l-naphtyl-2-(5-hydroxy-l-
methyl-2-pyridinemethylene) hydrazine chloride can be 30 
made by the same procedure replacing 3-hydroxy-2-
pyridine aldehyde with 2-formyl-5-hydroxy pyridine. 
2-Hydrazonomethyl-3-hydroxy-J,6-dimethyl pyridin-
ium chloride, 1-methyl-2-(1,6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydrazine chloride, I-methyl-I- 35 phen y 1-2-( l, 6-dimeth y 1-3-hydroxy-2-pyridinemethy-
Jene) hydrazine chloride, and 1, l-diphenyl-2-(1,6-
dimethy-3-hydroxy-2-pyridinemethylene) hydrazine 
chloride can be made by the same procedure replacing 
3-hydroxy-2-pyridine aldehyde in the above example 40 
with 3-hydroxy-6-methyl-2-pyridine aldehyde. 
EXAMPLE 11 
Preparation of 
ocarbony l)hydrazono ]methyl]-3-hydroxy-1-methyl 
pyridinium chloride, 3-hydroxy-J-methyl-2-[[(N-naph-
tylaminocarbonyl) hydrazono]methyl]pyridinium chlo-
ride, and 2-[[[N-(l-chloro-2-naphtyl)amino carbonyl]-
hydrazono ]methyl]-3-hydroxy-1-methyl pyridinium 
chloride can be made by the same procedure replacing 
4-phenylsemicarbazide in the above example respec-
tively with 4-phenyl-3-thiosemicarbazide, 4,4-diphenyl-
semicarbazide, 4,4-dimethyl-3-thiosemicarbazide, 4-
ethyl-3-thiosemicarbazide, 4-(2-naphtyl)semicarbazide 
and 4-(1-chloro-2-naphtyl)semicarbazide. 5-Hydroxy-l-
methyl-2-[[(N-phenylaminothiocarbonyl)hydrazono]-
methyl]pyridinium chloride, 5-hydroxy-1-methyl-2-
[[(N-phenylaminothiocarbonyl) hydrazono]methyl]-
pyridinium chloride, 2-[[(N,N-diphenylaminocar-
bonyl)hydrazono ]methyl]-5-hydroxy-1-methyl pyridin-
ium chloride, 2-[[(N,N-dimethylaminothiocarbonyl) 
3-H ydroxy-1-methy 1-2-[[ (N-phen y laminocarbony l)hy-
drazono ]meth y l]pyridinium chloride (3b) 
3-Hydroxy-2-[[(N-phenylaminocarbonyl)hy-
drazono]methyl]pyridine. 4-Phenyl semicarbazide (4.91 
g, 33 mmol) was added to a suspension of 3-hydroxy-2-
pyridine carbaldehyde (4.0 g, 33 mmol) in a mixture of 50 
ethanol water (30 mL: 40 mL). The reaction mixture 
was stirred at room temperature for 3 h and the yellow 
product was collected by filtration. The yellow precipi-
tate was washed with EtOH/H20 I: I and dried under 
P20s to yield 8.22 g (99%) of product. It can be recrys- 55 
tallized from EtOH/H20; m.p. 201'-2' C. (dee.). IH 
NMR (d6·DMSO) 8: 10.85 (br.s., IH); 10.6 (br.s., IH); 
9.14 (s, IH); 8.27 (s, IH); 8.15 (d of d, IH); 7.55 (d, 2H); 
7.26-7.36 (m, 4H); 7.01 (t, IH). 
hydrazono]methyl]-5-hydroxy-l-methyl pyridinium 
chloride, 2-[[(N-ethylaminothiocarbonyl) hydrazono]-
methyl]-5-hydroxy-1-methyl pyridinium chloride, 5-
hydroxy-l-methyl-2-[[ (N-naphty laminocarbony I )h y-
45 drazono]methyl]pyridinium chloride, and 2-[[[N-(l-
chloro-2-naphtyl)amino carbonyl]hydrazono]methyl]-
5-hydroxy-1-methyl pyridinium chloride can be made 
by the same procedure replacing 3-hydroxy-2-pyridine 
aldehyde with 2-formyl-5-hydroxy pyridine. 
EXAMPLE 12 
Preparation of l-Methyl-2-[[(N-phenylaminocarbonyl) 
hydrazono]methyl]pyridinium chloride (3d) 
2-[[(N-Phenylaminocarbonyl)hydrazono]methyl]-
pyridine. Pyridine-2-Aldehyde (5. 7 mL, 0.06 mol) was 
added to a suspension of sodium acetate (4.92 g, 0.06 
mol) and semicarbazide (9.07 g, 0.06 mol) in 60 mL of 
water. The resulting mixture was stirred at room tem-
60 perature for 14 hand the solid in suspension was filtered· 
and washed thoroughly with water. After drying, the-
semicarbazone was obtained as a dark beige solid (12.54 
g, 87%) and was used in the next step without further 
3-Hydroxy-2-[[(N-phenylaminocarbonyl)hy-
drazono]methyl]-l-methyl pyridinium chloride. Methyl 
iodide (7.2 mL, 0.12 mol) was added to a suspension of 
2-[[(N-phenylaminocarbonyl) hydrazono]methyl]-3-
hydroxy pyridine (3.72 g, 15 mmol) in 50 mL ofacetoni-
trile. The reaction mixture was placed in two pressure 65 
glass vessels and heated at 70° C. for 3 days. The solid 
which filled the reaction flasks was filtered and tritu-
rated well with warm (40° C.) acetone. The product 
purification; m.p. 181°-182° C. 
1-Methyl-2-[[(N-pheny Jaminocarbonyl )hydrazono ]-
methyl]pyridinium chloride. 2-[[(N-Phenylaminocar-
bonyl)hydrazono]methyl]pyridine (4.47 g, 0.02 mol) 
was divided into two pressure glass tubes and dissolved 
5,180,831 
33 34 
stirred at room temperature for 1.5 h. The silver iodide 
was filtered through Celite and the filtrate was concen-
trated to dryness in vacuo to yield a residue which is 
triturated with acetone. The resulting solid is filtered 
in acetonitrile (20 mL each). Methyl iodide was then 
added (2.6 mL each, 0.04 mol), the tubes were tightly 
closed and heated at 65° C. for 3 days. The reaction 
flasks were cooled to 10°-15° C. and the solid was fil-
tered. The yellow solid was washed with acetone and 
ether and dried to yield 6.66 g (92%) of the iodide salt; 
m.p. 192°-193° C. (dee.). It was dissolved in 400 mL of 
acetonitrile/water l: 1 and exchanged with freshly made 
AgCl (from 5.92 g of AgN03 and excess cone. lICl, 
washed well with water). The resulting suspension was 
stirred at room temperature for 2 h. The silver iodide 
was filtered off and the filtrate was concentrated to 
dryness in vacuo to yield a yellow solid that was tritu-
rated with acetone and ether. It was filtered and dried 
to yield 4.86 (96%) of the pure chloride salt as a yellow 
solid; m.p. 187°-188° C. (dee.). IH NMR (d6-DMSO) 8: 
11.87 (s, lH); 9.45 (s, lH); 8.98 (d of d, 2H); 8.56 (t, lH); 
5 and recrystallized from CH3CN/EtOH and acetone to 
yield 2.44 g (62%) of the pure chloride salt; m.p. 
194°-195° C. (dee.). Anal. Calcd. for C11H16CINs03x 
0.96 H20: C, 41.42; H, 5.66; N, 21.96; Cl, 11.12. Found: 
C, 41.42; H, 5.72; N, 21.81; Cl, 11.20. 
10 2-[[(Aminocarbonyl)hydrazono]methyl]-3-(N,N-
dimethylcarbamoyl)hydroxy-l,6-dimethyl pyridinium 
chloride can be made by the same procedure replacing 
3-hydroxy-2-pyridine aldehyde in the above example 
with 3-hydroxy-6-methyl-2-pyridine aldehyde. 2-
15 [[(Aminocarbonyl)hydrazono]methyl]-5-(N,N-dime-
thylcarbamoyl)hydroxy-l-methyl pyridinium chloride 
can be made by the same procedure replacing 3-
8·43 (s, lH); 8.01 (t, lH); 7.62 (d, 2H); 7·34 (t, 2H); 7·08 hydroxy-2-pyridine aldehyde in the above example with (t, lH); 4.36 (s, 3H). Anal. Calcd. for C14H1sCJN40 x 2 ~ l 5 h d ·d· 0.48 H20: C, 56.15; H, 5.37; N, 18.71; Cl, 11.84. Found: 20 - ormy - - Y roxy pyn me. 
C, 56.15; H, 5.38; N, 18.69; CJ, 11.88. EXAMPLE 14 
EXAMPLE 13 Preparation of 
Preparation of 
2-[[(Aminocarbonyl)hydrazono]methyl]-3-(N,N-dime-
thylcarbamoyl)hydroxy-1-methyl pyridinium chloride 
(4a) 
3-(N, N-Dimethylcarbamoyl )hydroxy-1-methyl-2-[[ (N-
25 phenylaminocarbonyl) hydrazono]methyl] pyridinium 
chloride (4b) 
2-[[(Aminocarbonyl)hydrazono]methyl]-3-hydroxy 
pyridine. Sodium acetate (2.21 g, 16 mmol) was dis-
solved in 25 mL of water and then semicarbazide hy- 30 
drochloride was added (l.81 g, 16 mmol), followed by 
3-hydroxy-2-pyridine aldehyde (2.0 g, 16 mmol). The 
resulting mixture was stirred at room temperature for 2 
h. The solid in the reaction mixture was then filtered, 
washed with water and dried to yield 2.71 g (93%) of 35 
the semicarbazone. It was used in the next step without 
further purification; m.p.: 215°-217° C. (dee.). 
2-[[(Aminocarbonyl)hydrazono]methyl]-3-(N,N-
dimethylcarbamoyl)hydroxy pyridine. The semicarba-
zone obtained in the previous step (2.71 g, 15 mmol) was 40 
suspended in 20 mL of pyridine and then N,N-dimethyl-
carbamyl chloride was added (4.2 mL, 45 mmol). The 
reaction flask was sealed with a septum and the mixture 
was stirred at room temperature for 20 h. The reaction 
mixture becomes a clear solution after one hour and the 45 
product begins to come out of solution after 2 h. When 
the reaction is complete, the mixture is cooled to 5 ° -10° 
C. in ice bath and filtered. The beige solid that results is 
washed with acetone/ether 1:1 and dried to yield 3.63 g 
(96%) of the carbamate which is used in the next step 50 
without further purification; m.p. 182°-3° C. (dee). 
2-[[(Aminocarbonyl)hydrazono]methyl]-3-(N,N-
dimethylcarbamoyl)hydroxy-1-methyl pyridinium 
chloride. The carbamate obtained in the previous step 
(3.63 g, 14 mmol) was dissolved in 50 mL hot (90° C.) 55 
DMF. When a clear solution was obtained, the reaction 
flask was cooled under running water until the inner 
temperature reached 26° C. Methyl iodide (6.3 mL, 100 
mmol) was then added and the reaction mixture was left 
at 65° C. in a Parr shaker for 3 days. The solvent was 60 
removed in vacuo to yield a dark viscous residue which 
was triturated with acetone. The yellow solid that re-
sulted was washed with acetone/ether 1:1, then with 
ether and dried to yield 5.15 g (94%) of the methiodide. 
Freshly made AgCI (from 4.45 g AgN03 and excess 65 
cone. HCI) was washed well with water and added to a 
solution of the methiodide (5.15 g, 13 mmol) in 200 mL 
acetonitrile/water l: l. The resulting suspension was 
3-(N ,N-Dimethylcarbamoy l)hydroxy-2-[[ (N-
pheny Jaminocarbony l)hydrazono ]methyl] pyridine was 
prepared by reaction of dimethylcarbamyl chloride (16 
mL, 0.18 mo!) with 3-hydroxy-2-[[(N-phenylaminocar-
bonyl)hydrazono]methyl] pyridine (4.5 g, 17.5 mmol) in 
30 mL of pyridine. The resulting mixture was stirred at 
room temperature for 6 h and poured over 500 mL of 
crushed ice. The beige precipitate was collected, 
washed thoroughly with water and dried to yield 5.48 g 
(95%) of product, m.p. 178°-180° C. The product (5.48 
g, 16.7 mmol) was dissolved in acetonitrile/DMF and 
then methyl iodide (2. 78 mL, 44. 7 mmol X 3 vessels) was 
added to the reaction vessel. The resulting mixture was 
stirred at 70° C. for 3 days and cooled in a water-ice 
bath for 30 min. The precipitate was collected by filtra-
tion, washed with acetone/ether 1:1 and dried to yield 
6.42 g (82 % ) of the methiodide salt. It was dissolved in 
500 mL H20 and 300 mL acetonitrile and then freshly 
made AgCI (2 eq, washed well with water) was added. 
The resulting suspension was stirred at room tempera-
ture for 2 h. It was filtered through Celite and the fil-
trate was concentrated to dryness in vacuo to a crisp 
yellow foam that becomes a yellow solid after tritura-
tion with acetone. The yellow solid was filtered, 
washed with ether and dried to yield 4.83 g (93%) of 
pure product as the chloride salt; m.p. 176°-177° C. 
(dee.). Anal. Calcd. for C11H20CIN503 x 0.84 H20: C, 
51.95; H, 5.56; N, 17.82; Cl, 9.02. Found: C, 51.95; H, 
5.55; N, 17.80; Cl, 9.11. 
5-(N,N-Dimethylcarbamoyl)hydroxy-1-methyl-2-
[[(N-phenylaminocarbonyl) hydrazono]methyl] pyri-
dinium chloride can be made by the same procedure 
replacing 3-hydroxy-2-pyridine aldehyde with 2-for-
myl-5-hydroxy pyridine. 
EXAMPLE 15 
Preparation of 
2-(3-Hydroxy-1-methyl-2-pyridinemethylene)-1-[2( 1-
pyridinium)acetyl]hydrazine dichloride (Sa) 
2(3-Hydroxy-2-pyridinemethy Jene )-1-[2-pyridinium-
)acety J] hydrazine chloride. 1-(Carboxymethyl) pyri-
35 
5,180,831 
dinium chloride hydrazide (2.63 g, 0.014 mol) in 10 mL 
36 
hydroxy-1-pyridinium)acetyl] hydrazine dichloride, 
and 2-(5-hydroxy-1-methyl-2-pyridinemethylene )-1-[2-
(l-piperidinium)acetyl] hydrazine dichloride can be 
made by the same procedure replacing 3-hydroxy-2-
pyridine aldehyde with 2-formyl-5-hydroxy pyridine. 
EXAMPLE 16 
Preparation of 
2-(1-Methyl-2-pyridinemethylene )-1-[2-( 1-pyridinium-
of methanol was added to a solution of 2-aldehyde-3-
hydroxy pyridine (1.72 g. 0.014 mol) in 20 mL of 
CH3CN. The resulting dark yellow solution is stirred at 
room temperature for 2 h and at the end of this period 5 
a beige solid filled the reaction mixture. Ethyl ether was 
added (10 mL) and the reaction mixture was cooled to 
5°-10° C. before filtering the beige precipitate. The 
solid was washed with ethyl ether and dried to yield 
3.72 g (91%) of product; m.p. 229°-30° C. (dee). 10 )acetyl] hydrazine dichloride (Sb) 
2-(3-Hydroxy-1-methyl-2-pyridinemethylene)-1-[2-
(1-pyridinium)acetyl] hydrazine dichloride. The acyl 
hydrazone obtained in the previous. step (3.5 g, 0.012 
mol) was divided into three pressure glass vessels and 
each portion was dissolved in 20 mL of acetonitrile. 15 
Methyl iodide was added to these solutions (1.2 mL 
each, 0.02 mo!) and the resulting mixtures were heated 
2-(2-pyridinemethylene )-1-[2-(l-pyridinium)acetyl] 
hydrazine chloride. 1-(Carboxymethyl) pyridinium 
chloride hydrazide (5.25 g, 28 mmol) and pyridine-2-
carbaldehyde (2. 7 mL, 28 mmol) were dissolved in 25 
mL acetonitrile: methanol (4:1). The resulting mixture 
was stirred at room temperature for 2 h, with the prod-
uct beginning to come out of solution after 20 min of 
reaction. After 2 h the white solid in the reaction mix-
ture was filtered and washed with acetonitrile and 
ether. After drying, the product was obtained as a white 
solid (5.27 g, 68%) and was used in the next step with-
out further purification; m.p. 240°-241° C.(dec.). IH 
NMR (d6-DMSO) o: 12.43 (br.s., lH); 9.07 (d, 2H); 8.70 
(t, lH); 8.66 (d, lH); 8.24 (d of d, 2H); 8.19 (s, lH); 
8.01-7.90 (m, 2H); 7.48-7.44 (m, lH); 6.07 (s, 2H). 
2-(1-Methyl-2-pyridinemethylene )-1-[2-( 1-pyridini-
um)acetyl] hydrazine dichloride. The acyl hydrazone 
obtained in the previous step (2.88 g, 10 inmol) was 
divided into two pressure vessels and each portion was 
dissolved in 25 mL of DMF. Methyl iodide was added 
to these solutions (1.62 mL each, 25 mmol) and the 
resulting mixtures were heated at 70° C. for 3 days. The 
solvent was removed in vacuo to yield a dark residue 
at 70° C. for 3 days. The reaction mixtures were concen-
trated in vacuo to a dark residue which was triturated 
with acetone/ethanol 5:1. The resulting yellow solid 20 
was washed with acetone/ethanol 5:1 and dried to ob-
tain 4.39 g (84%) of the iodide salt, m.p. 193°-94° C. 
(dee). Freshly made AgCI (from 3.43 g of AgN03 and 
excess cone. HCI) was washed well with water and 
added to a solution of the iodide salt (4.39 g, 0.01 mol) 25 
in 300 mL acetonitrile/water 1: I. The resulting suspen-
sion was stirred at room temperature for 2 h. The silver 
iodide was filtered through Celite and the filtrate was 
concentrated to dryness in vacuo to yield a solid that 
was triturated with acetone. The dark beige solid was 30 
filtered, washed with acetone and dried to yield 2.89 g 
(84%) of pure product as the chloride salt; m.p. 
230° -31' C. (dee.). Anal. Calcd. for C14H16Cl2N402 x 
0.96 H20: C, 46.65; H, 5.01; N, 15.55; Cl, 19.67. Found: 
35 which was triturated with acetone. The resulting solid 
was filtered, washed with acetone and ether and dried 
to yield 4.25 g (quantitative) of the methiodide as a 
yellow solid. Freshly made AgCl (from 3.77 g AgN03 
and excess cone. HCI) was washed well with water and 
C, 46.65; H, 4.95; N, 16.33; Cl, 20.66. 
2-(3-Hydroxy-1-methyl-2-pyridinemethylene )-1-[2-
(trimethylammonium)acetyl]hydrazine dichloride, 1-[2-
( 4-ch~o~o-1-pyridinium)acetyl]-2-(3-hydroxy-1-methyl-
2-pyndmemethylene) hydrazine dichloride, 1-[2-(3-car-
boxy-1-isoquinolinium)acetyl]-2-(3-hydroxy-1-methvl- 40 
2-pyridinemethylene) hydrazine dichloride, 1-[2-(2-~ar­
boxy-4-methoxy-1-quinolinium) acetyl]-2-(3-hydroxy-1-
methyl-2-pyridinemethylene) hydrazine dichloride, 2-
(3-hydroxy-1-methyl-2-pyridinemethylene )-1-[2-( 3-
hydroxy-1-pyridinium)acetyl] hydrazine dichloride, 45 
2-(3-hydroxy-1-methyl-2-pyridinemethylene )- I-[2-(2-
methyl-1-piperidinium) acetyl] hydrazine dichloride 
can be made by the same procedure replacing 1-(car-
~oxymet~yl) pyridinium chloride hydrazide respec-
tively with (carboxymethyl)trimethylammonium chlo- 50 
ride hydrazide (Girard's reagent "T"), 4-chloro-1-(car-
boxymethyl)pyridinium chloride hydrazide, 3-carboxy-
1-(carboxymethyl)isoquinolinium chloride hydrazide, 
2-carboxy-4-methox y-1-( carboxymethy l)quinolinium 
chloride hydrazide, 3-hydroxy-1-(carboxymethyl)- 55 
pyridinium chloride hydrazide, and 1-methyl-1-(carbox-
ymethyl) piperidinium chloride hydrazide. 2-(5-
Hydroxy-1-methyl-2-pyridinemethylene)-1-[2-( 1-
pyridinium)acetyl] hydrazine dichloride, 2-(5-hydroxy-
1-methyl-2-pyridinemethylene)-1-[2-(trimethylammoni- 60 
um)acetyl] hydrazine dichloride, 1-[2-(4-chloro-l-
pyridinium )acetyl ]-2-( 5-hydroxy-1-methy 1-2-
pyridinemeth y lene) hydrazine dichloride, l-[2-(3-car-
boxy-l-isoquinolinium)acetyl]-2-(5-hydroxy-1-methyl-
2-pyridinemethylene) hydrazine dichloride, 1-[2-(2car- 65 
boxy-4-methoxy-1-quinolinium)acetyl]-2-(5-hydroxy-1-
methyl-2-pyridinemethylene) hydrazine dichloride, 2-
(5-hydroxy-1-methyl-2-pyridinemethylene )-1-[2-(3-
added to a solution of the iodide salt (4.18 g, 10 mmol) 
in 200 mL acetonitrile/water 1:1. The resulting suspen-
sion was stirred at room temperature for 1.5 h. The 
silver iodide was filtered through Celite and the filtrate 
was concentrated to dryness in vacuo to yield 3.63 g of 
a yellow solid. Recrystallization from ethanol/acetone 
affords the pure chloride as a beige solid (3.0 g, 92%); 
m.p. 209°-210° C. (dee). IH NMR (d6-DMSO) o: 9.13 
(d, 2H); 9.08 (d, 2H); 8.75-8.59 (m, 4H); 8.26 (t, 2H); 
8.10 (m, lH); 6.19 (br.s., 2H); 4.42 (s, 3H). Anal. Calcd. 
for C14H16Cl2N40 x 0.91 H20: C, 48.94; H, 5.23; N, 
16.31; Cl, 20.64. Found: C, 48.94; H, 5.25; N, 16.31; Cl, 
20.43. 
EXAMPLE 17 
Preparation of 
0-Diphenylmethy l-N-(3-hydroxy-1-methyl-2-
pyridinemethy lene) Hydroxylamine Iodide 
O-Diphenylmethyl-N-( 3-hydroxy-2-pyridinemethy-
lene) hydroxylamine. 0-Diphenyl methyl hydroxylam-
ine hydrochloride (3.35 g, 14.2 mmol) was added to a 
solution of NaOH (0.57 g, 14.2 mmol) in 10 mL of H20. 
~fter the addition of 10 mL ofEtOH, 3-hydroxy-2-pyri: 
dme aldehyde (1.75 g, 14.2 mmol) was added. The mix-
ture was heated on a steam bath for I h. While the 
solution was allowed to cool an additional 30 mL of 
H20 was added. The product precipitated out as yellow 
needles. The mixture was filtered to isolate the pure 
product (3.8 g, 89%), m.p. 83°-84° C. IH NMR 
37 
5, 180,831 
(CDCl3) o: 9.S7 (s, lH); 8.40 (s, lH); 7.33 (s, lOH); 7.13 
(m, 3H); 6.23 (s, lH). Anal. Calcd. for C19H16N203: C, 
74.97; H, S.31; N, 9.21. Found: C, 74.88; H, S.32; N, 9.17. 
O-Diphenylmethyl-N-(3-h ydroxy-1-meth y 1-2-
pyridinemethy lene) hydroxylamine iodide. A solution 5 
of O-diphenylmethyl-N-(3-hydroxy-2-pyridinemethy-
lene) hydroxylamine (1.0 g, 3.29 mmol) in 4S mL of 
EtOH was placed in a glass pressure tube. Methyl io-
dide (0.9 mL, 13.8 mmol) was then added, and the tube 
was sealed tightly. The tube was heated at 69' C. in an JO 
oil bath for 20 h. The solvent was removed in vacuo, 
and the residue was triturated with acetone to give the 
product as a shiny dark yellow solid.(1.4 g, 9S%), m.p. 
163'-16S' C. The chloride salt can be obtained as de-
38 
rated with acetone to yield 3.6 g (86%) of pure product 
as a light beige solid, m.p. 17S 0 -6° C. (dee.). lH NMR 
(Me2SO-d6) o: 8.S2, 8.06 (s, lH); 8.10 (d, lH); 7.8S (t, 
lH); 7.30-7.4S (m, SH); S.30, S.20 (s, 2H); 4.1, 3.9 (s, 
3H); 2.69 (s, 3H). Anal. Calcd. for C15H11CIN202XO. lS 
H10: C, 60.96; H, S.90; N, 9.48; Cl, 12.00. Found: C, 
60.96; H, S.90; N, 9.Sl; Cl, 12.02. 
scribed above. 
0-( 1-Naphtylmethyl)-N-( 1,6-dimethy 1-3-hydroxy-2-
pyridinemethy Jene) hydroxylamine chloride, 0-(2-
meth y 1-1-naphtylmethy 1)-N-( l ,6-dimethyl-3-hydroxy-
2-pyridinemethylene) hydroxylamine chloride, O-meth-
yl-N-(l,6-dimethyl-3-hydroxy-2-pyridinemethylene) 
hydroxylamine chloride, 0-(p-chlorobenzy I )-N-( 1, 6-
15 dimethyl-3-hydroxy-2-pyridinemethylene) hydroxy-
EXAMPLE 18 
Preparation of 
O-Benzyl-N-(l,6-dimethyl-3-hydroxy-2-pyridinemethy-
lene) Hydroxy!amine Chloride 20 
3-Hydroxy-6-methyl-2-pyridine carbaldehyde. 3-
Hydroxy-6-methyl-2-pyridine methanol (20.0 g, 0.14 
mo!) and selenium dioxide (8.0 g, 72 mmol) were dis-
solved in 140 mL of 1,4-dioxane and 280 mL of absolute 
ethanol. The resulting mixture was heated at 80' -8S' C. 25 
for 12 h. The selenium precipitate was removed by 
filtration and the filtrate was concentrated to dryness in 
vacuo. The dark red residue was sublimed at 90' C. and 
14 mmHg for 6 h to obtain 11.0 g (S6%) of pure prod-
uct, m.p. 101° -102' C.; lH NMR (CDCl3) o: 10.50 (br s, 30 
lH), 10.03 (s, lH), 7.27 (s, 2H); 2.S3 (s, 3H). 
lamine chloride, O-(p-cyanobenzyl)-N-(l ,6-dimethyl-3-
hydroxy-2-pyridinemethylene) hydroxylamine chlo-
ride, 0-(2-hydroxy-4-nitrobenzyl)-N-(l,6-dimethyl-3-
hydroxy-2-pyridinemethylene) hydroxylamine chlo-
ride, 0-(p-methoxybenzyl)-N-( 1,6-dimethy 1-3-hydroxy-
2-pyridinemeth ylene) hydroxylamine chloride, 0-(p-
dimethyl aminocarbonyloxybenzyl)-N-(l,6-dimethyl-3-
hydroxy-2-pyridinemethylene) hydroxylamine chlo-
ride, 0-(p-propylaminocarbonyl benzyl)-N-(l,6-
dimethyl-3hydroxy-2-pyridine methylene) hydroxylam-
ine chloride, 0-benzyl-N-[3-(N' ,N' -dimethylcar-
bamoy l)hydroxy-1, 6-dimethyl-2-pyridinemethy Jene]-
hydroxylamine chloride, 0-benzyl-N-[3-(N',N'-diethyl-
carbamoyl)h ydroxy-1,6-dimethy 1-2-pyridineme-
th y lene ]hydroxy lamine chloride, 0-benzyl-N-[3-(N' ,N' -
di fl uoroethy Jcarbamoy l)hydroxy-1,6-dimethy 1-2-
pyridinemethy lene ]h ydroxylamine chloride, 0-(di-
phen y Im ethyl )-N-[3-(N' ,N' -dimethy Jcarbamoyl)h y-
droxy-1, 6-dimeth yl-2-pyridinemethylene ]hydroxy !a-
mine chloride, 0-(diphenylmethyl)-N-[l,6-dimethyl 
-3-(N' -isopropylcarbamoy l)hydroxy-2-pyridineme-
th y lene ]hydroxy lamine chloride, 0-(diphenylmethyl)-
N-[3-[N' -(2-fluoroethyl)carbamoyl]hydroxy- l ,6-
dimethyl-2-pyridinemethylene]hydroxylamine chlo-
ride, 0-(p-methoxybenzyl)-N-[3-(N' ,N' -dimethylcar-
bamoy l)hydroxy-1, 6-dimethy 1-2-pyridinemethylene ]-
O-Benzyl-N-(3-hydroxy-6-methyl-2-pyridinemethy-
lene) hydroxylamine. Sodium hydroxide (3.2 g, 0.08 
mo!) was dissolved in 80 mL of a 1:1 mixture of 
ethanol/water and then 0-Benzylhydroxylamine hy- 35 
drochloride (12.77 g, 0.08 mo!) was added. The reaction 
mixture was stirred at room temperature and when a 
clear solution was obtained 11.0 g (0.08 mo!) of 3-
hydroxy-6-methyl-2-pyridine carbaldehyde was added 
and the resulting mixture was stirred at room tempera- 40 
ture for 11 h. The reaction mixture was cooled in an ice 
bath and filtered to yield l 8.S3 g (96%) of product as a 
white solid, m.p. 81°-82° C. IH NMR (Me2SO-d6) o: 
9.8S (br s, lH), 8.40 (s, lH), 7.30-7.47 (m, SH), 7.22 (d, 
lH), 7.13 (d, lH), S.22 (s, 2H), 2.36 (s, 3H). 
0-Benzyl-N-( 1,6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydroxylamine iodide. O-Benzyl-
N-(3-hydroxy-6-methyl-2-pyridinemethylene) hydroxy-
lamine (10.0 g, 0.04 mo!) was dissolved in 7S mL of 
acetonitrile and 7. 7 mL (0.12 mo!) of methyl iodide. The 50 
reaction mixture was heated in a pressure glass vessel at 
90° C. for 3 days. The solvent was removed in vacuo 
and the residue was triturated with acetone to yield 8.1 
45 hydroxylamine chloride, 0-(p-methoxybenzyl)-N-[3-
(N' ,N' -dimethylcarbamoyl)hydroxy-1-ethyl-6-methyl-
2-pyridinemethylene ]hydroxylamine chloride, 0-(p-
methoxybenzyl)-N-[3-(N' ,N '-dimeth y Jcarbamoy l)h y-
g of a yellow solid. Recrystallization from acetone/E-
tOH/Et20 yields S.S g (3S%) of pure product as a pale 55 
yellow solid, IH NMR (Me2SO-d6) o: 8.SS (s, lH); 7.92 
(d, lH); 7.87 (d, lH); 7.30-7.48 (m, SH); S.2,S.33 (s, 2H); 
3.93,4.08 (s, 3H); 2.72 (s, 3H). 
O-Benzyl-N-(l,6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydroxylamine chloride. 0-Benzyl- 60 
N-( l ,6-dimethyl-3-hydroxy-2-pyridinemethy Jene) hy-
droxy !amine iodide (S.S g, 14 mmol) were dissolved in 
700 mL of water and 4.1 g (28 mmol) of freshly pre-
pared AgCI (from silver nitrate and excess cone. HCI) 
was then added. The suspension was stirred mechani- 65 
cally for 2.S hat room temperature and the silver iodide 
was then removed by filtration. The filtrate was con-
centrated to dryness in vacuo and the residue was tritu-
droxy-1-benzyl-6-methy 1-2-pyridinemethylene ]hydrox-
ylamine bromide, N-[3-(N' ,N' -dimethylcarbamoyl)hy-
droxy-1,6-dimethyl-2-pyridinemethy Jene ]hydroxy I a-
mine chloride, l,6-dimethyl-3-hydroxy-2-[[(N-
phenylaminocarbonyl)hydrazono ]methyl]pyridinium 
chloride, 1,6-dimethyl-3-hydroxy-2-[[(N-phenylamino-
thiocarbonyl) hydrazono ]methyl]pyridinium chloride, 
l,6-Dimethyl-2-[[(N,N-diphenylaminocarbonyl) hy-
drazono]methyl]-3-hydroxy pyridinium chloride, 2-
( 1,6-dimethy 1-3-hydroxy-2-pyridinemethylene )-1-[2-( 1-
pyridinium)acety l]hydrazine dichloride, 2-(1,6-dimeth-. 
y 1-3-hydroxy-2-pyridinemethylene )-1-[2-( trimethylam-
monium)acetyl]hydrazine dichloride, and 2-(1,6-
dimethy 1-3-hydroxy-2-pyridinemethylene )-1-[2-( 4-
chloro-1-pyridinium )acety l]hydrazine dichloride can be 
made by the same procedure replacing 3-hydroxy-2-
pyridine carbaldehyde with 3-hydroxy-6-methyl-2-pyri-
dine carbaldehyde. 
5, 180,831 
40 39 
EXAMPLE 19 
Preparation of 
O-Benzyl-N-(l-benzyl-3-hydroxy-2-pyridinemethy-
lene) hydroxylamine bromide 5 
O-Benzyl-N-(3-hydroxy-2-pyridinemethylene) hy-
droxylamine. 0-Benzyl hydroxylamine (10.4 g, 65 
mmol) was added to a solution of NaOH (2.6 g, 65 
mmol) in 66 mL of H20/EtOH 1:1. 3-Hydroxy-2-pyri- 10 
dine carbaldehyde (8.0 g, 65 mmol) was added to this 
solution and the resulting mixture was stirred at room 
temperature 3 h. The white precipitate was then filtered 
and dried to yield 13.3 g (90%) of pure product, m.p. 
64°-65° C. IH NMR (CDCl3) o: 9.72 (s, lH); 8.37 (s, 15 
lH); 8.13 (d of d,J=2Hz,J=4Hz, lH); 7.33 (m, 7H); 
5.17 (s, 2H). 
0-Benzyl-N-( 1-benzy 1-3-hydroxy-2-pyridinemethy-
lene) hydroxylamine bromide. Benzyl bromide (0.78 
mL, 6.6 mmol) was added to a solution of 0-benzyl-N- 20 
(3-hydroxy-2-pyridine methylene) hydroxylamine (1.0 
g, 4.4 mmol) in 4 mL of acetonitrile. The resulting mix-
ture was heated at 65° C. in a pressure bottle for 3 days. 
The solvent was removed in vacuo and coevaporated 
with water to leave an oily residue that was dissolved in 25 
100 mL of water and treated with activated charcoal. 
This mixture was filtered through Celite and the filtrate 
was concentrated to dryness under high vacuum. Ace-
tone (20 mL) was added to the residue and the product 
crystallized as light beige needles (1.5 g, 86%), m.p. 30 
145°-146° C. IH NMR (CDCl3) o: 8.68 (s, IH); 8.63 (d 
of d, lH); 8.52 (t, lH); 7.69 (d of d, lH): 7.35 (m, SH): 
7.10 (m, 2H): 6.12 (s, 2H); 5.25 (s, 2H). Anal. Calcd. for 
C20H19BrN202: C, 60.16; H, 4.80; N, 7.02; Br, 20.02. 
35 Found: C, 59.89; H, 4.86; N, 7.00; Br, 19.91. 
0-Benzyl-N-( l-benzyl-5-hydroxy-2-pyridinemethy-
lene) hydroxylamine bromide can be made by the same 
procedure replacing 3-hydroxy-2-pyridine aldehyde in 
the above example with 2-formyl-5-hydroxy pyridine. 40 
TABLE I 
Kinetic Constants for the Reversible Inhibition of Electric Eel 
TABLE II-continued 
Kinetic Constants for the Irreversible Inhibition of Electric 
Eel and Human Ervthrocyte Acetykholinesterase. 
kobsl[I] (eel) kobsl[l] (human) Ki (eel) 
com pd (M-ls-1) (M-ls-1) (µM) 
14000' 19000 NT" 
0 NT. not tested (inhibition half-life is too shon to measure accuratelyJ: 
bpyridostigmine: 
'k0 b,l[I] = 843 M- 1s- 1 (Forsberg. A. and Puu. G .. Eur. J. Btochem. 1984. 140. 153.); 
dphysostigmine: 
'kob/[I] = 18500 M- 1s- 1 (Forsberg. A. and Puu. G .. Eur. J. Biochem. 1984. 140. 
153.). 
TABLE III 
Jn Vivo Evaluation of Pyridinium Derivatives as Intramuscular 
Pretreatment Agents Against GD in Mice. 
LD50 time0 dose6 
com pd (µmol/kg) (min) (µmol/kg) % survival 
la 180 15/60 3.0-45 J0-20 
lb >880 15/60 22 0/JO 
Id >320 15/60 9.6 J0/20 
le >760 15/60 320/81 40/JO 
If >6J0 15/60 3J0/77 30/20 
lg >514 15/60 16/260 10/20 
2a 0.5 15/60 0.009-0.14 80-90 
2b 22 15 0.30 90 
1.4 60 
5.4 30 
60 0.30-5.4 60-70 
2c 84 15/60 0.005-0.11 50-70 
2d 600 15/60 9.0 90/90 
37 90/70 
150 5010 
3b >40 15/60 1.3/5.2 0/20 
3c >560 15/60 0.017-0.28 40-70/30-40 
3d >430 15/60 0.013-0.215 20-40/10-30 
4a >1240 15/60 0.2 50190 
0.6 80/100 
2.3 80/80 
4b 42 15 0.65 90 
2.7 90 
II 40 
4b 60 0.65-11 70-80 
5a >670 15/60 18-290 70-100/20-70 
5b 380 15/60 0.6 40/20 
24 100/30 
96 100/100 
and Human Ervthrocvte Acetylcholinesterase. °Compound!-> were tested at two different time intervals to allow for difference~ m 
bioavailabil11y: 
K1 (eel) K1 (human) IC50 (eel) IC50 (human) 
45 
"rhree different doses were tested. only one dose is recorded for inactive com· 
_c_o_m...;p_d--'-µM _____ ._µ_M ____ µ._M ____ µ._M___ pound,. 
la 40 JOO JOO 175 
lb 500 >600 
Jc 
Id 
le 
If 
3a 
3b 
4b 
5a 
Sb 
30, 3406 
85 
JO 
c 
100 
20 
c 
0 NI. no inhibition at concentrations up to I mM. 
NI" NI" 
400 >500 
400 >500 
NI" NI" 
325 300 
240 
40 40 
brwo distinct Kjs with eel AChE. multiple binding with both enzymes. 
'Multiple binding observed, only IC50 values determined. 
50 
55 
TABLE IV 
In Vivo Evaluation of Pyridinium Derivatives as Oral 
Pretreatment Agents Against GD in Mice. 
LDso time0 dose6 
com pd (µmol/kg) (min) (µmol/kg) % survival 
lb 3600 30/120 60 30/70 
le >3200 30/120 200 0!50 
2a 220 30/120 3.4 90/80 
2b 490 30/120 120 90/100 
2c 140 30/120 2.2 100/100 
4b 670 30/120 JO 70/100 
5a 2900 30/120 730 40/50 
°Compounds were tested at two different llme intervals to allow for differences in 
TABLE II bioavailability: 
----------------------- 60 "Three different doses were tested. only one dose is recorded for inactive com· 
Kinetic Constants for the Irreversible Inhibition of Electric 
Eel and Human Erythrocyte Acetylcholinesterase. 
kobsl[I] (eel) kobsl[I] (human) K1 (eel) 
compd (M-ls-1) (M-ls-1) (µMl 
2a 1700 68000 NT" 
2b 870 1100 NT" 
2c 5000 > 110000 NT" 
4a 25 2200 JOO 
Pyrb 580< 13000 NT" 
65 
pounds. 
TABLE V 
In Vivo Evaluation of Pyridinium Derivatives as Reactivators 
Against GD in Mice. 
LD50 dose" 
compd (µmol/kg) (µmol/kg) % survival 
la 180 2.8 20 
41 
5,180,831 
TABLE V-continued 
In Vivo Evaluation of Pyridinium Derivatives as Reactivators 
Against GD in Mice. 
corn pd 
lb 
Id 
le 
If 
lg 
2a 
2b 
LDso dose0 
(µmol/kg) (µmol/kgl 
>880 5.6 
>320 40 
> 760 20 
>610 12 
>514 15 
0.5 0.009-0.14 
22 0.33 
1.4 
5.4 
2c 84 1.3 
3a >1100 27b 
11ob 
43ob 
6.8 
54 
430 
3b >40 1.3 
3c >560 0.28 
3d >430 0.215 
4a 9.6 0.2-2.3 
4b 42 0.65-11 
5a >670 18-290 
5b 380 6 
24 
96 
2-PAMCI 853 53 
Hl-6 4500 280-1125 
o/c survival 
20 
20 
0 
0 
0 
30-50 
20 
70 
60 
20 
50 
70 
90 
20 
0 
70 
10 
10 
20 
0-50 
30-50 
70-90 
20 
40 
90 
0 
90-100 
°Three different doses were tested. only one dose 1s recorded for inactive com-
f:'.unds: 
adjunct efficacy test. see text for details. 
TABLE VI 
In Vivo Evaluation of Pyridinium Derivatives as Reactivators 
Against GA in Mice. 
LDso dose 
corn pd (µmol/kgl (µmol/kg) CJ;- survi\'a1° 
le > 1970 30 0 
If 2100 33 0 
lg >510 16 0 
2a 0.5 0.009 30 
2c 84 0.005 20 
4a 9.6 0.60 20 
4b 670 2.70 30 
5a >670 18 10 
73 80 
290 90 
5b 380 6 10 
24 0 
96 80 
"Three different doses were tested. only one dose is recorded for inactive com-
pound!-. 
What is claimed is: 
1. A compound of the group consisting of the formu-
las: 
xll I Y and 
"' II N~ CH=NNH-C-NR2R3 
I 
z 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
42 
and any counterion to make pharll)aceutically accept-
able salts, wherein 
Z is selected from the group consisting of C1-6 alkyl, 
C1-6 alkyl with an attached phenyl group, C1-6 
alkyl with an attached naphthyl group, C1-6 alkyl 
with two attached phenyl groups, C1-6 alkyl with 
an attached phenyl group mono, di or trisubstituted 
with J, C1-6alkyl with two attached phenyl groups 
mono, di or trisubstituted with J, C1-6alkyl with an 
attached naphthyl group mono, di, or trisubstituted 
with J, 
wherein J is selected from the group consisting of 
halogen, COOH, OH, CN, N02, NH2, C1-6 alkyl, 
C1-6 alkoxy, C1-6 alkylamine, C1-6, alkyl-0-CO-, 
C1-6 alkyl-0-CO-NH-, C1-6 alkyl-NH-CO-NH-, 
C1-6alkyl-NH-CO-O-, C1-6aklyl NH-CO-, 
(C1-6 alkyl)2N-CO-, 
wherein X is selected from the group consisting of 
OH, C1-6 alkyl-NH-CO-O-,(C1-6 alkyl)2-
N-CO-O, C1-6 fluoroalkyl-NH-C0-0, (C1-6 
fluoroalkyl)i-NH-C0-0, 
Y is 0 or S, 
wherein R2 is selected from the group consisting of 
H, C1-6 alkyl, phenyl, C1-6 alkyl with an attached 
phenyl group, C1-6 alkyl with an attached phenyl 
group mono, di, or trisubstituted with K, C1-6 alkyl 
with an attached naphthyl group, C1-6 alkyl with 
an attached naphthyl group mono, di, or trisubsti-
tuted with K, 
wherein R3 is selected from the group consisting of 
H, C1-6 alkyl, phenyl, C1-6 alkyl with an attached 
phenyl group, C1-6 alkyl with an attached phenyl 
group mono, di or trisubstituted with K, 
wherein K is selected from the group consisting of 
halogen, COOH, OH, CN, N02, NH2, C1-6 alkyl, 
C1-6 alkoxy, C1-6 alkylamine, C1-6 alkyl-0-CO-, 
C1-6 alkyl-0-CO-NH-, C1-6 alkyl-
NH-CO-NH-, C1-6 alkyl-NH-C0-0-, 
C1-6 alkyl NH-CO-, (C1-6 alkyl)2N-CO-, 
wherein B is selected from the group consisting of H, 
C1-6 alkyl. 
2. A compound of the group consisting of the formu-
las: 
X1ll I . Y and 
"' II N CH=NNH-C-il4 I+ 
z 
~X1 
~ Jl fi 
B N CH=NNH-C-il4 
,+ 
z 
with any counterion to make pharmaceutically accept-
60 able salts, wherein 
X1 is selected from the group consisting of H, OH,. 
C1-6 alkyl-NH-C0-0-, (C1-6 alkyl)z-
N-C0-0-, C1-6 fluoroalkyl-NH-C0-0-, 
(C1-6 fluoroalkyl)i-NH-C0-0-, 
65 Y is 0 or S, 
Z is selected from the group consisting of C1-6 alkyl, 
C1-6 alkyl with an attached phenyl group, C1-6 
alkyl with an attached naphthyl group, C1-6 alkyl 
43 
5, 180,831 
44 
with two attached phenyl groups, C1-6 alkyl with 
an attached phenyl group mono, di or trisubstituted 
with J, C1-6alkyl with two attached phenyl groups 
mono, di or trisubstituted with J, C1-6alkyl with an 
attached naphthyl group mono, di, or trisubstituted 5 
with J, 
wherein J is selected from the group consisting of 
halogen, COOH, OH, CN, N02, NH2, C1-6 alkyl, 
C1-6 alkoxy, C1-6 alkylamine, C1-6 alkyl-0-CO-, 
C1-6 alkyl-0-CO-NH-, C1-6 alkyl- 10 
NH-CO-NH-, C1-6 alkyl-NH-C0-0-, 
C1-6 alkyl NH-CO-, (C1-6 alkyl)2N-CO-, 
wherein R4 is selected from the group consisting of 
C1-6alkyl with a pyridinium ring attached through 
nitrogen, C1-6 alkyl with a pyridinium ring at- 15 
tached through nitrogen and mono, di, or trisubsti-
tuted with K, C1-6 alkyl with a quinolinium ring 
attached through nitrogen and mono, di, or trisub-
stituted with K, C:-6 alkyl with an isoquinolinium 
ring attached through nitrogen and mono, di, or 20 
trisubstituted with K, C1-6 alkyl-T, 
wherein T is selected from the group consisting of 
formula (I) and formula (II), 
R' 
I 
-N"'"-R" 
I 
R"' 
Formula I 
25 
Formula II 30 
wherein R', R", and R"' are selected from the group 35 
consisting of H, C1-6 alkyl, C1-6 fluoroalkyl, C1-6 
alkyl with an attached phenyl group, C1-6 alkyl 
with an attached phenyl group mono, di, or trisub-
stituted with K, C1-6 fluoroalkyl with an attached 
phenyl group mono, di, or trisubstituted with K, 40 
wherein K is selected from the group consisting of 
halogen, COOH, OH, CN, N02, NH2, C1-6alkoxy, 
C1-6 alkylamine, C1-6 alkyl-0-CO-, C1-6 alkyl-0-
CO-NH, C1-6 alkyl -NH-CO-NH-, C1-6 alkyl-
NH-C0-0-, C1-6 alkyl NH-CO-, (C1-6 alkyl)2 45 
N-CO, 
50 
55 
60 
65 
wherein B is selected from the group consisting of H, 
C1-6 alkyl. 
3. A compound of the formula: 
n fi 
N+ CH=NNH-C-NR7Rs 
I 
z 
with any counterion to make pharmaceutically accept-
able salts, wherein 
Y is 0 or S, 
Z is selected from the group consisting of C1-6 alkyl, 
C1-6 alkyl with an attached phenyl group, C1-6 
alkyl with an attached naphthyl group, C1-6 alkyl 
with two attached phenyl groups, C1-6 alkyl with 
an attached phenyl group mono, di, or trisubstitu-
ted with J, C1-6 alkyl with two attached phenyl 
groups mono, dis or trisubstituted with J, C1-6alkyl 
with an attached naphthyl group mono, di, or tri-
substituted with J, 
wherein J is selected from the group consisting of 
halogen, COOH, OH, CN, N02, NH2, C1-6 alkyl, 
C1-6alkoxy, C1-6alkylamine, C1-6alkyl-O-CO-, 
C1-6 alkyl-0-CO-NH-, C1-6 alkyl-
NH-CO-NH-, C1-6 alkyl -NH-C0-0-, 
C1-6 alkyl NH-CO-, (C1-6 alkyl)2N-CO-, 
R1 is selected from the group consisting of C1-6 alkyl, 
phenyl, C1-6 alkyl with an attached phenyl group, 
C1-6alkyl with an attached phenyl group mono, di, 
or trisubstituted with K, C1-6 alkyl with an at-
tached naphthyl group, C1-6alkyl with an attached 
naphthyl group mono, di, or trisubstituted with K, 
wherein Rs is selected from the group consisting of 
C1-6 alkyl, phenyl, C1-6 with an attached phenyl 
group, C1-6 alkyl with an attached phenyl group 
mono, di, or trisubstituted with K, 
wherein K is selected from the group consisting of 
halogen, COOH, OH, CN, N02, NH2, C1-6 alkyl, 
C1-6 alkoxy, C1-6 alkylamine, C1-6 alkyl-0-CO-, 
C1-6 alkyl-0-CO-NH-, C1-6 alkyl-
NH-CO-NH-, C1-6 alkyl-NH-C0-0, C1-6 
alkyl NH-CO-, (C1-6 alkyl)2N-CO-. 
* * * * * 
